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ABSTRACT
Understanding the Complexities of Anemia in Chronic Inflammatory
Diseases from Diagnosis to Treatment
Naomi Rae Flindt
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Iron is an essential nutrient for energy and DNA replication. Its homeostasis is commonly
perturbed by chronic inflammatory mechanisms. Chronic inflammation upregulates a cytokine,
hepcidin, that degrades the iron export protein ferroportin. Without a way to export iron into the
bloodstream iron availability in blood becomes depleted. Iron depletion in the blood stream
hinders erythropoiesis and is termed anemia. Herein I investigate and inhibit the mechanism of
hepcidin activation. Inhibition of hepcidin activation has released iron from tissues and alleviated
anemic conditions in a cancer model. I have laid the foundation to investigate this pathway in a
3D spheroid model. The results show that hepcidin 25 inhibition is a promising treatment for
anemia of cancer. More work needs to be done to confirm efficacy in an in vivo model. In
addition to anemia of cancer I have also worked with diabetic rats and investigated their anemic
state using common anemia diagnostic methods. I found that in this high fat high sugar diet
Wistar rat model anemia was not induced. In addition to my studies on anemia I have
investigated the use of portable x-ray fluorescence (pXRF) as an accessible and affordable
elemental analysis technique for lateral flow immunoassays and biological samples such as cell
lysates and animal tissue. While pXRF shows promising results more work needs to be done to
increase its sensitivity and pixel size.

Keywords: Ferroportin, Hepcidin, Anemia, Cancer, Furin, X-ray Fluorescence, Lateral Flow
Immunoassay
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1.
1.1

Introduction

An Introduction to Iron Pathology
Iron, the fourth most abundant element on the earth, is an essential nutrient for cell

growth and proliferation.2-4 Adult bodies contain anywhere from 3-5 g of iron.5, 6 The
chemistry that iron can perform is what makes it a unique and critical nutrient. Iron shuttles
electrons as it changes oxidation states between ferrous (Fe+2) to ferric (Fe+3) iron. Although
iron is found in other oxidation states, the ferrous and ferric oxidation states are most
biologically relevant. Ferrous and ferric iron have different binding properties, solubility’s,
preferred ligand preferences, coordination geometries, affinities etc. The ability of iron to
change oxidation states by 1-electron chemistry leads to radical chemistry that can be
damaging to biological systems. To protect against radical damage, the body tightly regulates
iron. Iron is often shuttled, bound, or chaperoned by other proteins.

The most abundant example of iron and its unique properties in the body is found in
hemoglobin (Hb). As shown in Figure 1.1 roughly 70% of iron in the body is bound in Hb and
stored in erythrocytes.5-7 The body generates 2 million erythrocytes every second in the bone
marrow through a process called erythropoiesis. Erythropoiesis is stimulated by erythropoietin
(EPO) a hormone released from peritubular cells in the kidney. EPO is stimulated by a lack of
oxygen.8 As the body senses low oxygen levels EPO stimulates erythroferrone (ERFE) which
has been shown to inhibit a protein hepcidin to allow more iron to be released for erythrocytes
1

Figure 1.1 Bodily Iron Distribution
Bodily iron distribution is a multi-organ process. 70% of iron is used for erythropoiesis.
25% of iron is split up among metalloproteins in muscles, macrophages, and transferrin
shuttling in the plasma. Hepcidin is a key cellular and systemic regular of iron export
and therefore acts as a gate keeper for iron into the plasma. Hepcidin is upregulated by
inflammatory signaling pathways via liver and macrophage signaling. Hepcidin is
inhibited by hypoxia induced pathways thus releasing iron from stores to promote
erythropoiesis.
synthesis.9 As developing erythroid progenitors mature, they gradually accumulate iron from
macrophages.10, 11 Iron sits in the center of the porphyrin ring in the ferrous iron (II) state where
it can bind to oxygen.12 The Fe-O2 interaction is not too strong thus allowing O2 to be released
under acidic conditions acting as an important oxygen shuttle throughout the body.12-14 Oxygen
is an essential nutrient for glucose and energy metabolism.12 There are many metabolic enzymes
and proteins that are dependent on oxygen as well as iron to produce glucose which is a building
block of porphyrin.12 This chemistry is critical for the survival of life.
2

In the body ferrous iron is the most relevant form of iron. Our bodies are only able to
directly absorb ferrous iron through our diet. In enterocytes divalent metal transferase-1 (DMT1) absorbs primarily ferrous iron since ferric iron (Fe+3) is insoluble and precipitates under
biological conditions.13 The acidic conditions of the gut favor the Fe+2 oxidation state.7 Other
indirect iron absorption are in the form of heme or ferritin (Ft). These are taken up by separate
absorption pathways.4
The next major iron reservoir in our body is the liver (Figure 1.1). About 25% of our
bodily iron is stored in the liver.6, 7 In liver hepatocytes, iron is stored in Ft, an iron storage
protein that stores up to 4,500 atoms of iron in the ferric state.13, 15 Generally, most of the stored
iron in the liver can be mobilized and used if bodily iron needs are not met. About 10% of our
bodily iron is stored as myoglobin in muscles and found in macrophages and other organs as
metalloproteins (i.e. Fe-S clusters). Macrophages play an important role in recycling senescent
erythrocytes through erythrophagocytosis. Thus, releasing iron back into the transferrin pool.16
Metalloproteins play important roles in oxygen sensing, transcription, metabolism, electron
transfer, and DNA synthesis.6
Lastly, roughly 0.1% of bodily iron is trafficked through the bloodstream in its ferric
state by a protein transferrin (TFN).5, 7 Under healthy physiological conditions about one third
of circulating TFN is saturated with iron. Iron absorbed from the intestinal enterocytes or
recycled from splenic macrophages performing erythrocyte turnover is exported into the
bloodstream by ferroportin (FPN). Once in the bloodstream TFN shuttles iron to budding
erythrocytes or to hepatocytes for storage. About one half of the circulating iron is lost daily to

3

Figure 1.2 Reactive Oxygen Generation via Fenton-Like Chemistry
Oxidative stress generation is a part of the healthy cell metabolism and produces O2- and H2O2.
These species are not reactive enough to participate in membrane degradation directly however,
these protective enzymes like superoxide dismutase (SOD), catalase (Cat), glutathione
peroxidase-1 (GPx) and peroxiredoxin (Prx) degrade superoxide and peroxide to benign species.
However, when superoxide and peroxide are oxidized further by unbound labile iron to generate
OH• which does have deleterious effects on cell membranes. Reformatted from Galaris et al,
2019.

things like blood loss or desquamation.17 This chaperoning and binding of iron by TFN is
important as it protects the cells from the deleterious effects of oxidative damage.

When iron is unchaperoned it can readily participate in redox chemistry to produce
reactive oxygen species (ROS) via Fenton-like chemistry shown in Figure 1.2. ROS can damage
lipids, proteins, DNA, and RNA among others. Chronic levels of inflammation or excess iron
4

can lead to higher levels of ROS as well as ferric iron. These become a major driving force of
ROS and therefore inflammatory diseases. Under chronic circumstances an abundance of ROS
and iron will deplete the levels of protective antioxidants and other chaperones in the body.18
When speaking about unchaperoned iron we often refer to the cytosolic labile iron pool (LIP)
inside the cells and the non-transferrin bound iron (NTBI) or Labile Plasma Iron (LPI).2, 5 The
increase in unprotected iron has no specific location. The excess unchaperoned iron in the LIP
contributes to the buildup of more ROS as shown in Figure 1.2. It is difficult to measure the
presence of labile ROS but as we see in the Fenton reaction their presence is often associated
with the presence of free unbound iron. Therefore, iron levels and the ratio of free ferric to
ferrous iron levels themselves can be a sign of oxidative stress levels.19
Due to the deleterious side effects of ROS, our bodies have mechanisms in place to
protect themselves from high levels of free iron and ROS. Excess iron is often stored away in Ft.
Any iron that is transferred extracellularly is chaperoned by transferrin. There are also known
iron response elements (IRE) in the mRNA of iron regulatory proteins that are shielded from
binding when iron is present. When iron levels become depleted this allows iron response
proteins (IRPs) to bind to the IREs in the mRNA. Depending on where the IRE is on the mRNA
it can prevent the initiation of translation (5’IRE bound to IRP) or protect the mRNA from
degradation (3’IRE bound to IRP). Ft, mAconitase and FPN mRNAs contain a 5′IRE while
DMT1 and transferrin receptor-1 (TfR1) transcripts have a 3′IRE.11 In addition to iron regulatory
proteins, antioxidants are also upregulated in response to free iron levels via nuclear factor
erythroid 2-related factor 2 (Nrf2). These iron regulatory responses are helpful in maintaining
iron homeostasis throughout the body and protecting from oxidative stress.

5

Iron can mediate autophagy, also known as ferroptosis via iron specific ROS
generation.20, 21 Ferroptosis mechanisms block transcription factor Nrf2 from binding to its
antioxidant response element (ARE) leading to a depletion of antioxidants (i.e. heme oxygenase1(HO-1), glutathione reductase, Cat, and GPx) and an abundance of iron mediated ROS thus
leading to cell death via iron generated ROS overload.21, 22 In the study of Chen et al.21 the
presence of iron chelators prevented ferroptosis response implying that free iron is indeed an
essential amplicant for ferroptosis mediated cell death.

Because iron is an essential resource for life and is found abundantly in the body it is also
useful for pathogens. Microbes can use ferroproteins to extract iron from their hosts. These
microbes also often secrete iron chelating proteins termed “siderophores”.13, 23 The small amount
of iron in the bloodstream bound to transferrin is the biggest target for microbes. Microbes also
seek out NTBI or free iron that has not yet bound to TFN. Our bodies have developed responses
to fight off these types of microbes and infection which are protective under acute circumstances.
Mechanisms such as the interleukin-6 (IL-6) inflammatory response prove to be protective to the
host as shown in Figure 1.3 below. IL-6 signals through the janus tyrosine kinase (JAK) signal
transducer and activator of transcription-3 (STAT-3) pathways. JAK phosphorylates STAT-3
which then homodimerizes and binds to a HAMP promoter region in the nucleus. HAMP is the

6

name of the gene that encodes hepcidin. Once HAMP gene expression is initiated, the mRNA is
made and translated into pre-prohepcidin by the ribosome. The pre-region targets hepcidin for
secretion. Once preprohepcidin enters the secretory pathway, the pre region of pre-prohepcidin is
cleaved from prohepcidin and prohepcidin moves into the golgi where it can be further cleaved
by the protease furin as shown in Figure 1.3.24 Furin cleaves the pro region resulting in hepcidin25 excretion from the cell as shown in Figure 1.4. Once excreted, hepcidin-25 binds to FPN
where the hepcidin/FPN complex is then ubiquitinated for proteasome degradation.4, 25, 26 When
FPN, the only iron export protein, is degraded, iron begins to accumulate in the cell. This leads
to depletion of iron in the bloodstream. Iron accumulated in the cell can be stored in Ft or used in
metabolic processes. The hepcidin mechanism is protective in acute scenarios of infection or
injury as it starves the microbe of iron, by storing up iron inside cells where microbes cannot
easily access it. This is a healthy response of cells to a bacterial infection.13
In response to iron overload, hepcidin is upregulated via the bone morphogenic protein-6
(BMP-6) pathway. BMP-6 signals through the suppressor of mothers against decapentaplegic
1/5/8 (SMAD 1/5/8) pathway. The BMP-6 receptor and other cellular mediators phosphorylate
SMAD 1/5/8 which then binds to SMAD-4. This complex then moves to the HAMP promoter
region in the nucleus. High levels of iron can cause increased inflammation and drive disease
progression in many diseases such as anemia, diabetes, fibrosis, arthritis, cancer, and
neurodegenerative diseases. Iron dysregulation can have severe consequences and often
promotes disease progression. Iron mediated oxidative stress can create a cycle of disease

7

Figure 1.3. Hepcidin/Ferroportin Axis
The hepcidin/ferroportin axis is regulated by the IL-6/STAT-3 pathway
in response to the immune system and by BMP-6/SMAD-1/5/8 in
response to endogenous iron levels. Both pathways upregulate HAMP
expression leading to increased levels of preprohepcidin
progression as disease is brought on by chronic inflammation that leads to prolonged
dysregulation of iron leading to increased inflammation to further disease progression.
These common inflammatory stimuli for hepcidin, IL-6 and BMP-6 are shown in Figure
1.3. These two pathways work together synergistically to upregulate the gene expression of
HAMP.9, 27, 28 However, as shown in Figure 1.3, other inflammatory stimuli are also known to
upregulate hepcidin. In response to iron overload, hepcidin is upregulated via the bone
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morphogenic protein-6 (BMP-6) pathway. BMP-6 signals through the suppressor of mothers
against decapentaplegic 1/5/8 (SMAD 1/5/8) pathway. The BMP-6 receptor and other cellular
mediators phosphorylate SMAD 1/5/8 which then binds to SMAD-4. This complex then moves
to the HAMP promoter region in the DNA. High levels of iron can cause increased inflammation
and drive disease progression in many diseases such as anemia, diabetes, fibrosis, arthritis,
cancer, and neurodegenerative diseases. Iron dysregulation can have severe consequences and
often promotes disease progression. This oxidative stress can create a cycle of disease
progression as disease is brought on by chronic inflammation that leads to prolonged
dysregulation of iron leading to increased inflammation to further disease progression.

1.2

Anemia of Chronic Inflammation Overview

Iron is known to accumulate in cells experiencing chronic inflammatory environments
common in diseases such as diabetes, chronic kidney disease (CKD) and cancer.29 This iron
accumulation in cells has a direct effect in upregulating a gene called HAMP as mentioned
earlier in Figure 1.3. The production of hepcidin is influenced mostly by circulating and tissue
iron levels (BMP-6) secondly it is influenced by infection/injury (IL-6), erythropoiesis/hypoxia
(ERFE), protein misfolding (CREBH), among other inflammatory signals.5, 9 Other common
inflammatory events or mechanisms that have an indirect effect on hepcidin regulation are
included in Table 1.1 below. This list shows the inter-relatedness of different inflammatory

9

pathways that can affect iron regulation via hepcidin response. It is apparent that hepcidin and
therefore iron plays a significant role in inflammatory diseases.

Table 1.1 Inflammatory Pathways and Diseases Associated with Hepcidin Levels
Pathways
JNK

Associated Diseases & Disorders
Arthritis

References
(Kanamori et al, 2018).

Cancer
TGF-β

Fibrotic diseases

(Peng et al, 2022).

Cancer
IFN- γ

Multiple Sclerosis

(Pollard et al. 2013)

Arthritis
TNF

Cancer

(Kunnumakkara et al,

Irritable Bowel Disease (IBD)

2018), (Chen & Ma, 2019)

Arthritis
Diabetes
Non-Alcoholic Fatty Liver Disease
NF-κβ

IDB

(Park & Hong, 2016)

Multiple Sclerosis (MS)
Arthritis
UV-radiation

30

Cancer
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In order to understand further how to regulate hepcidin as a treatment for inflammatory
disease we need to further understand how furin, the hepcidin activator, is regulated under
chronic inflammation. Pro-hepcidin has been shown to be found in the golgi and nucleus where it
autoregulates its own expression by binding to the HAMP promoter inhibiting its upregulation.31
Pro-hepcidin in the golgi is cleaved by furin. Prohepcidin can also be excreted from the cell but
at a lower rate than that of hepcidin-25.24 Figure 1.4 shows the furin consensus sequence on

Figure 1.4 Hepcidin Maturation Process
Hepcidin is a pre-proprotein. The prehepcidin is cleaved once it enters the secretory pathay. The
prohepcidin portion is cleaved next in the golgi activating the mature hepcidin-25 which is the
primary signalling portion of hepcidin. Figure modified from Poli et al.1
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hepcidin. Furin is a proprotein convertase (PC) in the family of prohormone convertases that
activate hormones by cleaving the inactive pro region.
Hepcidin is inhibited under hypoxic conditions through furin cleaving soluble
hemojuvelin (sHJV) a co-receptor to the BMP-6 receptor. Matriptase is another protease shown
to cleave HJV in a similar spot however yields a different product than that of furin cleavage.32
sHJV levels block BMP-2 and BMP-4 from upregulating furin and hepcidin.1, 32, 33 Although
furin activity attenuates hepcidin expression with sHJV activation, furin also contributes to
hepcidin activation. Under hypoxic conditions furin gene expression is also promoted via
hypoxia inducible factor-1α (HIF-1α) which is stabilized by iron deficiency.32 As one of the most
important PCs furin activates many inflammatory cytokines and receptors as shown in Figure 1.5
such as transforming growth factor β (TGF-β), insulin-like growth factor-1(IGFR-1), VEGF-C,
platelet derived growth factor (PDGF), hepatocyte growth factor (HGF), membrane-type 1
metalloproteinase (MT1-MMP), and tumor necrosis factor-alpha converting enzyme
(TACE/ADAM17), sterol regulatory element binding protein-1c (SREBP-1), and BMP-4.34, 35
Some of these activated pathways such as NF-κβ ,TGF-β, SMAD-2, SMAD-4, and PDGF
cytokines also promote increased gene expression of fur the gene encoding for furin.35-38 Furin
activation creates a cycle as its activity promotes an increase in its gene expression leading via
maturation of inflammatory signals that can then exponentially increase inflammatory
signaling.39, 40 Elevated furin levels have been associated with arthritis, obesity, type 2 diabetes,
and anxiety.35 Furin is important in processing viral targets like COVID-19 and HIV.35

12

Figure 1.5 Furin Mediated Inflammation Pathways
Furin is an important pro-protein convertase that has been shown to play a crucial role in many
cell related pathways from matrix remodeling to signaling. It is also crucial in activating viruses
(not shown in figure above).

While hepcidin has shown both systemic and cellular regulation of FPN, other
inflammatory pathways have been shown to contribute to FPN regulation outside of the
hepcidin/FPN axis. FPN transcription is upregulated by Nrf2 and downregulated by BTB and
CNC homology 1 (BACH1).22, 41 BACH1 is known to enhance ROS. BACH1 is commonly
found upregulated with age and diseases such as arthritis.22 On the translational level FPN
mRNA is silenced via iron response proteins and elements (IRPs and IREs) in response to iron
deficiency. FPN has been shown to be regulated on a cellular level by heme levels as well as zinc
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and cadmium levels through metal transcription factor-1 (MTP-1).17 Low FPN levels lead to iron
sequestration in cells whether that is tissues or erythrocytes. This accumulation of iron over
chronic periods can deplete protective proteins and chaperones leading to increased oxidative
damage that leads to a decrease in erythrocytes.17

Erythropoiesis depends on four things: proliferation of erythroid progenitor reserve,
potency of stimuli for erythropoiesis, nutrient disposability, and erythrocyte survival.12 As
mentioned earlier inflammation and disease upregulate many cytokines including IL-1, IL-6, IL10, and TNF. These inflammatory markers negatively regulate EPO by impairing proliferation
and differentiation of erythroid progenitors while stimulating erythrophagocytosis.12, 42 These
inflammation mediated impairments result in a lower number of erythrocytes. This can lead to
anemia with a reduced amount of iron available to make new red blood cells (hypoferremia) and
normal Ft levels.12 Ineffective erythropoiesis leads to fewer erythrocytes and increased hypoxia.
Hypoxia leads to and upregulation the of HIFs which are transcription factors that downregulate
hepcidin transcription.10, 12, 43 Essential nutrients for heme synthesis include glucose and iron.
Under hypoxic conditions glucose metabolism is slowed along with nutrient availability.12
Shortened erythrocyte survival occurs under inflammation as more macrophages undergo
macrophage polarization.12 Inflammation is also involved in suppressed erythropoiesis in bone
marrow. Alterations in iron metabolism, and oxygen use result in iron-restricted erythropoiesis
leading to the induction of hepcidin 16. The combination of interrupted iron delivery to the bone
marrow and inflammation induced inhibition of erythropoiesis cannot keep up with the rate of
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erythrocyte destruction.16 Erythrocyte destruction is increased from a higher amount of oxidative
stress and macrophage polarization. Patients with chronic inflammatory diseases such as cancer
or diabetes show decreased EPO synthesis via hypoxic stimuli and are inadequately too low to
keep up with the demands for Hb.12 As the energy metabolism and the nutritional status of
patients under inflammatory stress decline these same inflammatory signals perpetuate the
inflammation cycle.

In the body, systemic inflammatory signaling occurs primarily from macrophages in the
blood. Although hepcidin is primarily produced in the liver it has a systemic influence as a
cytokine. Other organs that have been shown to respond to and sometimes secrete hepcidin
include brain 44, 45, liver46, 47, spleen47, intestine46, kidneys48, lungs49, 50, prostate51, periodontal
tissues52, bone marrow49, and heart.53, 54 Hepcidin plays a role in many different organs and is
important in metabolism and nutritional uptake. The way hepcidin regulates metals is different
depending on the organ. For example, hepcidin has been shown to upregulate Fe, Mn, and Mo
content in the spleen whereas it only upregulates iron in the liver.47 Additionally, hypoxia has
shown to decrease hepcidin levels in the liver and increase cardiac hepcidin levels.54 These
findings imply that inflammation in one organ can cause systemic signaling that can impact other
organs as well. This is why understanding the effects of hepcidin on metal sequestration on a
systemic level is an important step in understanding the effects of inflammation on a systemic
level.
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1.3

Hepcidin as a Biomarker in Disease
Chronic diseases resulting in increased systemic inflammation may be associated with

increased hepcidin production, leading to the “anemia of chronic disease”.9 Hepcidin is a
biomarker for liver fibrosis and cirrhosis.54 Elevated Pediatric levels of hepcidin have been
correlated with juvenile idiopathic arthritis.55 Elevated hepcidin has also been shown to be
involved with an increased risk of cardiovascular events 56. Hepcidin-25 has been shown to be a
biomarker for inflammation status. Hepcidin has become a biomarker of interest in predicting
cancer severity and outcome. In a recent study 29 serum samples from a breast cancer clinical
trial in the early 1990’s were surveyed for hepcidin-25 levels using an ELISA. Results showed a
significant correlation of cancer resurgence in obese patients with high hepcidin levels. The
hepcidin results also significantly correlated well with iron indices. However, no trend was
observed in the overall cohort. While this data shows promise that hepcidin may be a useful
biomarker, some variables in this study could be causing different trends. One variable is that the
serum samples for this study were taken post-surgery and therefore could easily have elevated
IL-6 signaling from surgery alone leading to increased hepcidin levels systemically.
Alternatively, elevated hepcidin could be due to obesity alone thus fueling the higher hepcidin
levels.
In acute liver failure serum hepcidin levels have been shown to correlate with survival.
The lower the serum levels of hepcidin the lower the survival rate of the patient.57 Iron
deficiency anemia vs anemia of chronic inflammation could be better diagnosed if hepcidin
levels were measured.58 Hyperferritinemia in metabolic syndrome is easier to diagnose with
hepcidin level information.59 Hepcidin-25 has been shown to strongly correlate with Ft levels in
CKD and can aid in differentiating what type of therapy may be best. There have been mixed
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results of associating Hepdcidin-25 to inflammation markers like C-reactive protein (CRP) or IL6.60 These paradoxical outcomes may be due to the difficulty in probing Hepcidin-25.24 ESA
therapies have shown to be more effective when Hepcidin-25 levels are high in the patient
suggesting that hepcidin-25 markers would be useful in deciding on a treatment strategy.60
Atherosclerosis has been correlated with Hepcidin-25 levels in rheumatoid arthritis, nonalcoholic fatty liver disease, and menopausal women.60 Hepcidin has been correlated with low
energy availability in athletes and is being investigated as a biomarker.61 Hepcidin has been
shown to be a biomarker useful in diagnosing and treating anemia of inflammation.62 Despite the
many studies that have shown interesting correlations there is still no FDA approved hepcidin
test.

1.4

Anemia
Anemia in chronic disease (ACD) is the second most common type of anemia in the

world.63 Studies have shown that Hb is inversely correlated with inflammatory markers such as
hepcidin, EPO, Ft, and ROS species. This correlation shows that anemia can be brought about
by a variety of inflammatory avenues. Many studies show that anemia has a multifaceted
mechanism that is affected by nutrition, energy metabolism, and oxidative stress due to limited
oxygen transportation.12 The cardiovascular and renal systems are most affected as they
attempt to compensate for anemic conditions. Vasodilation and reduced vascular tone are
associated with increased cardiac output leading to symptoms such as paleness and vertigo.12
Lack of oxygen to essential organs is what causes other symptoms such as headache, lethargy,

17

depression, limited functional capacity, and fatigue.12 Immunodepression is another significant
side effect of anemia making anemic patients more susceptible to infection.12

Anemia of chronic disease is commonly diagnosed via a complete blood count (CBC)
among other blood parameters as shown in Table 1.2. In anemia of chronic inflammation
include Hb levels under 9 g/dL, significantly lower serum iron, increased Ft, and decreased
serum EPO, and low reticulocyte count. While iron deficiency anemia patients experience
normal hemoglobin levels with a decrease in serum iron and mean cell volume (MCV) or mean
cell height (MCH) while experiencing an increase in reticulocyte counts and EPO.
Distinguishing between these two scenarios of anemia is critical for understanding the
underlying driving force of the anemia.
Table 1.2 Diagnostic Biomarkers for Iron Deficiency
Anemia vs. Anemia of Chronic Disease
Feature Iron Deficiency
Anemia
Presence of Other Chronic Diseases rarely
Average Baseline Hb Concentration ≥ 9 g/dL
Serum Iron Concentrations decreased
MCV/MCH decreased
Serum Ferritin Concentration low
Serum Hepcidin Concentration low
% of Reticulocytes in the Blood Serum high
Serum Folic Acid Concentration normal
Serum Vitamin B12 Concentration normal
Serum Creatine Concentration normal
Serum EPO increased

Reformatted from Abbaspour et al.7
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Anemia of Chronic Disease
often
≤ 9 g/dL
significantly decreased
normal
increased
high
low
decreased
decreased
increased
decreased

It is important when treating anemia of chronic inflammation to understand how to
silence the inflammatory signaling of the chronic disease in order to sufficiently get nutrients
absorbed by the patient.7, 64 Current treatment options include oral, intravenous (IV), or
intramuscular iron supplementation.65, 66, 67 Oral treatments have a high percentage of mild side
effects and when a patient has inflammation their ability to absorb iron from the diet is severely
hindered. Additional supplementation with the combination of other treatments such as
erythropoietin stimulating agents (ESAs) has shown to sometimes be effective in aiding iron
uptake and ultimately increasing Hb levels.67, 68 ESAs do come with the risk of negative
cardiovascular events and are increasingly more expensive.68 Other issues that make oral iron
supplementation complex are effects of diet on iron absorption. There are many plant derived
compounds that inhibit iron absorption as well as other medications. Ascorbic acid and meats
can help to increase iron absorption.67, 68 IV iron supplementation is associated with more risks
as free labile iron introduced into an inflammatory environment with excess ROS can be a
catalyst for more oxidative stress. IV iron has also been associated with a higher risk of
infection.67 Blood transfusions work well in severe cases however they are not a long-term
solution as they come with serious risks such as iron overload, infectious disease,
immunosuppression, etc.12
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Figure 1.6 Treatment Methods for Anemia of Chronic Disease.
It is important to address anemia of chronic disease in three ways. First to address the underlying
cause of inflammation. This is important so that any iron supplementation can efficiently reach
the bone marrow. Second, is to consider the best supplementation method. Depending on
severity and other critical vitamin deficiencies. Lastly, to monitor the treatment plan for any
adverse side effects. Vitamin C is important for iron supplementation as it aids in the dietary
absorption of iron. Reformatted from Abbaspour et al. 7
When ACD is prevalent in patients iron supplementation may not be the best treatment as
the mechanisms and conditions described earlier result in iron overload for iron stores and cells
while the bloodstream remains iron deficient. Increasing iron supplementation will aid in
increasing the iron overload and thus perpetuating the inflammation and disease cycle. Other
treatments have been explored to mitigate hepcidin levels directly or indirectly to ultimately
release iron from iron stores and alleviate anemia.1, 8, 9, 12, 66-69, 70 Treatment strategies that target
the hepcidin/FPN axis to alleviate anemia are shown below in Figure 1.7. Mechanisms of action
that have been explored include inhibition of hepcidin production, protection of FPN activity
from hepcidin suppression, neutralization of circulating hepcidin, and suppression of hepcidininducing signals, such as the inflammatory pathway mediated by the cytokine IL-6.55 A potential
promising therapeutic approach to modulate hepcidin has emerged from the development of
hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These agents stabilize
hypoxia-inducible factors and subsequently improve anemia by stimulating endogenous EPO
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production and iron release from macrophages and enterocytes.71 Alternative strategies have
aimed at pharmacological modulation of hepcidin function by targeting different regulatory
steps, such as the BMP/HJV/SMAD pathway. The BMP/HJV/SMAD pathway is the primary
regulator of hepcidin expression in response to systemic iron levels. Other therapeutic
approaches include hepcidin sequestering agents (antibodies, anticalins, and RNA aptamers),
FPN stabilizers, inhibitors of BMP/SMAD, IL6/STAT3, or hepcidin transduction
(siRNA/shRNA) pathways.1
These emerging strategies to reduce or antagonize hepcidin can facilitate release of
endogenous iron from the reticuloendothelial system (RES) to the circulation which may reduce
ESA dose requirements and, consequently, reduce adverse cardiovascular events observed in
clinical trials.72, 73, 74

1.5

Inhibition of the Bottleneck Furin
Many angles to hepcidin inhibition and FPN stabilization have been explored in chronic

inflammatory models.25 From upstream antibodies and inflammatory inhibitors to direct
inhibitors of hepcidin, none of these treatments have proven sufficient to inhibit hepcidin in
humans in a pharmaceutically acceptable manner. Inhibition of inflammatory pathways using
drugs or antibodies that block the Jak/STAT3 pathway or the BMP/SMAD pathway have not
been successful due to the simultaneous activation of multiple inflammatory pathways (Figure
1.7). This is further complicated by additional systemic inflammation that occurs through many
convoluted signaling pathways that are not yet fully understood. Other inflammatory pathways
(Figure 1.7). This is further complicated by additional systemic inflammation that occurs
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Figure 1.7 Therapeutic Strategies to Alleviate Anemia of Chronic Inflammation
Many groups have attempted to regulate the FPN/hepcidin axis through inhibiting individual
inflammatory pathways through BMP-6, JAK/STAT, or EPO targeting. Others use antibodies
to target hepcidin or FPN specifically to prevent binding. No groups have explored the effect
of furin inhibition on the FPN/hepcidin axis. It has the potential to attenuate hepcidin
regardless of the inflammation stimulus that is upregulating its expression.

through many convoluted signaling pathways that are not yet fully understood. Other
inflammatory pathways are beginning to emerge as potential hepcidin regulators such as GDF22

15.75 This makes it difficult for drugs that target one specific inflammatory cytokine or pathway
to work effectively. The attempts to bind and clear hepcidin have proven difficult by the quantity
of antibodies or other binding molecules required to clear hepcidin and by the fact that hepcidin
rebounds rapidly after clearance due to continued inflammation.
An alternative route, that has been investigated with some promising results, is to target
the hepcidin activating PC furin. Even though furin may be expressed at high levels under
inflammatory states, its enzymatic protease activity may be altered by other factors in the diet. It
has been shown that curcumin can inhibit the activity of furin leading to better disease outcome
for COVID-19.76 Other groups have investigated furin silencing in cancer decreased tumor
progression as well as the inflammatory response.38 Other groups have inhibited cancer
metastasis via bone targeted furin inhibition to prevent inflammatory mechanisms and breast
cancer bone metastasis.77 There are known furin inhibitors like Decanoyl-Arg-Val-Lys-Argchloromethylketone (CMK).78 In cancer however, furin ablation in the liver has shown to be an
ineffective treatment in treating liver carcinoma in mice.79 This may be due to the fact that
SREBP-1 was inhibited which led to the mislocalization of lipids. This in turn shows that
completely knocking out furin may be too extreme.
We propose the use of HIV protease inhibitors, a class of drugs that have been
extensively reviewed and are already FDA approved.80, 81, 82, 83, 84 HIV protease inhibitors have
been used for many years in HIV treatment. They have also been found to have anti-tumor
effects which have been reviewed.85 Nelfinavir has been shown to have the best antitumor effects
in comparison to other HIV protease inhibitors. In previous studies the effect of these protease
inhibitors on hepcidin and therefore anemia has never been explored. We propose the use of
Nelfinavir to inhibit Hepcidin-25 activation via furin inhibition. By inhibiting the activation of
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hepcidin through furin inhibition, we can attenuate hepcidin regulation regardless of the source
of inflammation This will aid in stabilizing FPN, restoring iron to the serum and eventually to
the bone marrow. Ultimately, we will be able to treat the anemic conditions via FPN stabilization
while simultaneously mitigating the cancer progression. This is a unique approach to anemia as
well as inflammatory diseases such as cancer and diabetes.
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2.

HIV-Protease Inhibitor, Nelfinavir, Stabilizes Ferroportin to Alleviate Anemia in
Cancer
Naomi Flindt, Steve Christiansen, Grant Flindt, Alexis Gardner, Paulina Medellin, Annie Taylor,
Jacob Parker, Roger Woolley, Ellis Truman, Clayton Grundvig, Phillip Smit, Richard Watt
2.1

Abstract
Anemia of Cancer is commonly found in 50-65% of breast cancer patients upon

diagnosis. Anemic breast cancer patients have a lower chance of survival and prognoses. It has
been found the patients with high FPN levels have a 90% chance of survival. Many groups have
targeted the hepcidin/FPN axis to stabilize FPN however, there is still no FDA approved
treatment. We have employed the use of an FDA approved HIV protease inhibitor, Nelfinavir, to
stabilize FPN and alleviate anemic symptoms. In this study we investigated the effect of
Nelfinavir on FPN stabilization using 2D and 3D tumorigenic MCF-7 cell culture models. In our
2D results we were able to observe that Nelfinavir significantly inhibits furin activity. Inhibition
of furin was correlated with a significant decrease in the furin mediated Hepcidin-25 activation.
Hepcidin-25 inhibition led to a significant increase in FPN levels. We observed trends showing
that iron was released when treated with Nelfinavir. These preliminary results show that
Nelfinavir has potential to treat of anemia in cancer. More work needs to be done to understand
the pleiotropic effects of Nelfinavir on anemia as well as anticancer pathways.

2.2

Introduction

Anemic conditions are found in about 45-60% of breast cancer patients and increase to
about 90% post chemotherapy.86 Anemia of cancer has a significant impact on patient outcomes.
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Anemia can affect quality of life by decreasing energy levels and cognitive function. Side effects
common in anemia of cancer include fatigue, lethargy, depression, patient morale,
immunodepression, and reduced treatment efficacy.12 Iron is an essential nutrient for cell
growth and proliferation.2, 4, 29 Sequestered iron intensifies malignant phenotypes of several
cancers, including breast cancer to drive cancer growth through metabolic processes.6, 12, 14, 30,
43, 51, 66, 85, 87, 88, 89

Breast cancer cells exhibit a perturbed iron metabolism, giving them a

metabolic advantage over neighboring cells to accumulate iron.
Breast cancer cells accumulate iron through the hypoxia induced upregulation of the
iron uptake protein transferrin receptor-1 (TFR-1).90 Elevated TFR-1 allows the breast cancer
cells to accumulate iron. Additionally, cancer cells were shown to have elevated levels of the
hormone hepcidin.29, 50, 91 High levels of hepcidin are associated with the degradation of the
only iron export protein ferroportin (FPN).4, 8, 13, 70, 85, 92 Without a way for iron to exit the cell,
iron accumulates in the cancer cells and iron is depleted from the bloodstream. The
combination of elevated TFR-1 to accumulate iron and the secretion of hepcidin to prevent iron
release through FPN degradation, allows cancer cells to accumulate iron for metabolic
purposes. This occurrence leads to the development of anemia of cancer, a common symptom
of aggressive cancers.12, 87
The mechanism of tumor aggressiveness ties back to inflammation. In a study of 133
breast cancer patients, it was found that 35% of cancer patients had anemia upon diagnosis. The
more severe the prognosis correlated with a higher incidence of anemia as well as inflammatory
markers (hepcidin, IL-6, Ft, and ROS).87 While hepcidin is primarily expressed and secreted
from the liver, it has been shown to also be produced at lower levels in other organs,
macrophages and epithelial breast cells.8, 12, 29, 75, 85 Hepcidin is upregulated by various
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inflammatory pathways an anemia focused set of inflammatory pathways are shown in Figure
1.7. Common injury related inflammatory pathways such as those activated by interleukin 6 (IL6) and bone morphogenic protein (BMP-6) increase hepcidin.8, 75, 89 IL-6 and BMP-6
synergistically upregulate the gene expression of HAMP via the JAK/STAT-3 and SMAD 1/5
pathways respectively. HAMP is translated into a pre-proprotein that is subsequently activated
through proteolytic cleavage of the pre and pro regions. Pro-hepcidin is the inactive precursor of
hepcidin and prohepcidin cleavage by the protease, furin, produces active hepcidin-25. Active
hepcidin-25 is secreted into the bloodstream where it binds to and degrades membrane bound
FPN, the only iron export protein in the cell.4, 70, 85 This regulatory axis of FPN via hepcidin-25 is
heavily dependent on the post-translational modification of prohepcidin via the protease furin.

Although the inflammatory response is healthy and protective in acute scenarios, it can
become a breeding ground for cancers under chronic conditions. Chronic inflammation can
initiate cancer related DNA mutations from ROS induced DNA damage.12 These same chronic
inflammatory pathways also increase matrix remodeling proteins to enhance cancer metastasis.
Up to 20% of cancer deaths are linked to inflammation or chronic infection.8, 35, 72, 87, 93 As shown
in Table 2.1 many inflammatory events diseases are linked with the potential outcome for
associated cancers. This can include inflammation from chronic irritation. One example includes
chronic bronchitis from smoking as a predisposition for lung cancer. Another is someone with
IBD has an increased risk for bowel cancer. Obesity and arthritis are also linked with lymphoma
development.35
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Table 2.1 Inflammatory Diseases Associated with Cancers
Inflammation/ Infection

Related Cancer

References

Colorectal

94

Lung

95

Liver

79

Gastritis/helicobacter pylori

Stomach

96

Alcohol, pancreatitis

Pancreas

97

Cervicitis/papilloma virus

Ovarian

98

Prostatitis

Prostate

99

Cystitis and Schistosoma

Bladder

100

Sunburn/ultraviolet light

Melanoma

101

Esophagitis/Gastric acid, alcohol,

Esophageal

102

Non-Hodgkin’s lymphoma,

103

Ulcerative colitis, Autoimmune
Diseases
Emphysema, Tobacco,
tuberculosis, Macular
Degeneration
Hemochromatosis, hepatitis Band
C, Alcohol, obesity

haematobium

tobacco
AIDS

Kaposi’s sarcoma
Rheumatoid arthritis

Non-Hodgkin’s lymphoma,

104

Hodgkin lymphoma
Epstein-Barr virus

Nasopharyngeal carcinoma, Burkitt

105

lymphoma
Multiple Sclerosis, Obesity

Breast

106

Periodontitis

Oral

107
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In breast cancer, both the tumor and immune cells express inflammatory cytokines.12, 108
These inflammatory cyokines include IL-6, HIF1, VEGF, TNF, mTOR, hepcidin, etc. lead to the
polarization of M1 macrophages. These polarized macrophages can retain more iron further
aggravating anemic conditions.12, 109 In response to inflammation and reduced production of
EPO, EPO receptor are increased in cancer and correlated with poor erythrocyte maturation.110
When nutrient pools like iron are reduced in the cell, mTOR activation inhibits Hb synthesis.12
Low Hb synthesis will in turn lead to low oxygen (O2) levels (hypoxia) which has been
correlated with a negative effect on the efficacy of antineoplastic treatment.12, 16, 34, 35, 39, 87
Although many inflammatory pathways can have an effect on hepcidin and tumorigenicity, we
are focusing on a narrow scope of inflammation that has shown to directly interact with iron
regulatory proteins. The scope of our inflammatory model Figure 1.7 focuses on IL-6 and BMP6 pathways and their effect on hepcidin.

Due to the role that cancer tissues and immune cells play in inflammatory signaling it is
important to understand the role of the tumor microenvironment on hepcidin signaling. Recent
work has shown that inflammatory signaling and HAMP gene expression are significantly
increased when MCF-7 tumorigenic breast epithelial cells are grown in 3D cell culture as
opposed to 2D cell culture as shown in Figure 2.1.75 Pro-hepcidin levels have been shown to be
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significantly increased in 3D spheroid breast cancer cell models when compared to 2D cell
culture.8 This shows that hepcidin signaling pathways vary depending on the model used. As

Figure 2.1 2D v 3D Signaling Models in Breast Cancer
2D culture models have simplified signalling pathways in comparison to that
of 3D tumor models. The increased signalling and increased inflammatory
pathays present in a 3D model have been shown to increase hepcidin ;eve;s.
This increase in hepcidin may lead to an increased in iron dysregulation and
therefore could be a more realistic tumor environment. Understanding of the
effects of treatment on a 3D spheroid may helpful in understanding treatemnt
efficacy.

shown in BMP-6 signaling is significantly increased in the 3D model. This group also found that
hypoxia induce GDF-15 plays a role in upregulating hepcidin in 3D culture models that is not
present in 2D cultures.8 They found that 3D spheroids co-cultured with tumor fibroblasts allowed
for the IL-6 signaling to increase pro-hepcidin expression further. Recent reviews suggest the
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role that tumor assisted macrophages can also play on hepcidin regulation in the tumor
microenvironment.89 These findings stress the importance of using more realistic tumor models
in cancer research and drug discovery.

Pinnix et al.85 investigated FPN levels in various breast cancer cells lines including:
HME, R5, SUM19, SUM102, MCF-7, and MCF-10a. They compared the tumorigenic epithelial
cell lines and their corresponding non-tumorigenic controls. The results show that tumorigenic
cells have significantly lower FPN expression and higher pro-hepcidin expression than that of
the non-tumorigenic cell lines. This group went on to investigate ferroportin stabilization as a
therapeutic method for tumorigenicity. They found that when mice were given knock-in FPN
tumor xenografts they had significantly smaller tumors than mice that were given control
xenografts.
In this same study, breast cancer patients with high FPN mRNA levels were found to
have a 90% chance of cancer survival after 10 years. In contrast, cancer patients with low FPN
mRNA levels, have only a 65% chance of survival after 10 years.85 Thus, finding a treatment to
stabilize FPN, in other words prevent FPN from being degraded by hepcidin-25 induced
degradation, is imperative to increasing cancer patient survival rates. Herein, we investigate the
role that the hepcidin plays on FPN stabilization in anemia of cancer.
As mentioned in the introduction, treatments to inhibit hepcidin have focused on
inhibiting the inflammatory signaling pathways of Jak/STAT or BMP/SMAD. Figure 1.7
depicts a few of the signaling pathways that have been detailed in attempts to understand
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hepcidin inhibition and FPN stabilization.68, 70 Small molecule inhibitors of these pathways or
expensive antibodies that target these upstream inflammatory signaling pathways to inhibit
hepcidin have been attempted (Figure 1.7). Upstream inhibition of hepcidin has proven to be
problematic because in many cases, multiple inflammatory signaling pathways are activated at
the same time so inhibiting only one pathway is insufficient to stop the production of hepcidin.
As mentioned earlier there are many known inflammatory cytokines that participate in hepcidin
activation.75 Because hepcidin depletion treatments do not appear effective, the ability to
stabilize FPN has also been attempted. FPN agonist strategies include antibody stabilizers but
currently no treatments have made it to market.70 Despite the prevalence of anemia in breast
cancer, the only treatment options include ESAs when chemotherapy induces anemia. Other
targeted treatments for anemia have yet to be approved.12, 66

A new mechanism we are proposing is to target the protease Furin to inhibit Hepcidin-25
activation to thus stabilize FPN. Furin is the most studied PC in cancer and is elevated in all
human cancer types including breast cancer. Furin leads to increased tumor activation, migration
and inflammation signaling.34, 35, 38, 77, 111-113 Inhibition of furin in breast cancer cells decreased
cancer tumorigenicity and proliferation.113 Loss of furin in T-cells represses mammary
tumorigenesis in triple negative breast cancer.111 Furin inhibition via Sunitib treatment showed a
decreased migration and activation of MCF-7 cells via decreased interaction between furin and
substrates pro-VEGF-C 114 and pro-MT1-MMP.112 Furin targeting in Ewing’s Sarcoma,
colorectal cancer also showed promising results.38 However, furin KO in liver carcinoma has
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shown to be an ineffective treatment in mice.79 This may be because SREBP-1 was inhibited
which led to the mislocalization of lipids. This in turn shows that completely knocking out furin
may be too extreme. These findings suggest that furin is a viable target for aiding in cancer
treatment. Additionally, furin inhibition has the potential to aid in stabilizing FPN to alleviate
anemic conditions. Although furin inhibition has been actively studied no groups have made the
connection between furin inhibition to FPN stabilization.
Our goal is to inhibit hepcidin and stabilize FPN in a way that is independent of any
inflammatory pathway. To be independent of inflammatory pathways, the inhibition must be
downstream of translation. Preprohepcidin is synthesized followed by two cleavage steps that
accompany targeting to the secretion pathway and activation by furin. We identified Furin as a
potential site of inhibition because without the cleavage of prohepcidin to hepcidin, there is no
biological activity that degrades FPN. Through a series of computer docking, enzyme assays,
tissue culture studies and animal studies we discovered that some of the HIV protease inhibitors
have favorable binding affinities to inhibit furin. We suggest that HIV Protease inhibitors, which
have been extensively reviewed and are already FDA approved, can be used for FPN
stabilization to alleviate anemia of cancer.

HIV protease inhibitors have been used since 1995.115 It is also well documented that this
class of protease inhibitor also exhibits strong anti-tumor effects.80 Although many other anticancer properties have been detailed, Furin inhibition and subsequent FPN stabilization has
never been documented before our lab made this discovery. The HIV protease inhibitor
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Nelfinavir has been involved in several cancer related clinical trials (NCT01728779,
NCT00589056, NCT02066311, NCT00589056, NCT01065844) as a chemosensitizer and has
been shown to have significant anti-tumor effects and is the drug investigated herein.81, 82, 84, 116
We hypothesize that the use of HIV protease inhibitors will inhibit Hepcidin-25 activation via
Furin inhibition. Inhibition of hepcidin activation should lower active hepcidin levels, regardless
of the source of inflammation. In turn, decreased active hepcidin will stabilize FPN
concentration and ultimately should treat the anemic conditions and mitigate cancer progression.
This is a unique approach to treat anemia of cancer as well as cancer aggression in breast cancer
cells.
In this study we evaluate the efficacy of inhibiting IL-6 and BMP-6 stimulated hepcidin
activation via furin inhibition using the HIV protease inhibitor Nelfinavir. The objective of this
study is to show that hepcidin inhibition via Nelfinavir will restore FPN levels in cancer cells and
prevent cancer cells from accumulating iron, subsequently resulting in less cancer proliferation
and tumor aggression. We aim to evaluate hepcidin activation, FPN expression, and iron
homeostasis in breast cancer cell models. Using these models, we will use Nelfinavir as a furin
inhibitor to block the activation of prohepcidin to hepcidin to lower hepcidin-25 levels and
increase levels of FPN. We propose that furin inhibition with Nelfinavir will alter cancer cell
viability, growth rates, migration rates, intracellular iron levels, and levels of other iron
regulatory proteins that relate to cancer aggressiveness. Due to the narrow inflammatory scope of
our model we do not claim that this strategy will be anti-inflammatory however, it may aid in the
restoration of iron homeostasis alleviating anemia and iron mediated inflammation.
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2.3

Methods

Cell Culture: The 2D and 3D cell cultures of MCF-7 breast cancer cells were cultured using a
modified method from Blanchette-Farra et al5. Briefly, DMEM/F-12 (Corning 10-092-CV) with
10% FBS, 1% Pen-Strep-Amphotericin (Lonza 17-745E), 10 μg/mL bovine pancreas insulin
(Sigma 1882) and 5% CO2 at 37C. The MCF-10a were cultured using DMEM/F-12 with 5%
donor horse serum (R&D Systems S12150), 0.5 μg/mL hydrocortisone ((Sigma H-0888,), 20
ng/mL hEGF (Peprotech AF-100-15), 100 ng/mL cholera toxin (Sigma C-8052), 10 μg/mL
insulin, and 1% Pen-Strep-Amphotericin. Spheroid cell culture has 0.024% methylcellulose
(Sigma m-7027). Spheroids are cultured in a 2% agarose gel 3D spheroid plate made with a mold
that was a generous gift from the Van Ry lab at Brigham Young University.

Western Blotting: Cells were rinsed with PBS and scraped while on ice for lysis. Cells were
lysed with RIPA buffer, frozen in liquid nitrogen, thawed, and then stored at -20º C for long-term
storage. Protein quantifications are carried out with the Lowry protein assay. Protein samples are
prepared by adding 2.5-5 µL of 5x SDS sample loading buffer with β-mercaptoethanol and
samples were boiling for 5 minutes. Approximately 25 µg of protein are electrophoresed by
SDS-PAGE and transferred to a nitrocellulose membrane. Following transfer, the nitrocellulose
was rinsed in room temperature Tris Buffered Saline (TBS), dried for 10 minutes, and rehydrated
with Milli-Q water. The membranes were blocked with 5 mL of TBS, containing 5% BSA and
0.1% Tween, for 1 hour at room temperature. The membranes were then incubated overnight at
4º C with primary antibodies. Rabbit monoclonal antibodies, pSTAT3 (Y705, 9145S) and
pSMAD1/5 (s463/465, 9516S), purchased from Cell Signaling Technology were used in this
assay. Transferrin Receptor-1 (TFNR-1) was from Thermo Fisher Scientific (Rabbit pAb, PA535

27739). β-Actin (8H10D10, 3700S), a mouse monoclonal antibody, was also purchased from
Cell Signaling Technology for use as a loading control. Following overnight incubation,
membranes were rinsed 3 times for 5 minutes with 5 mL of TBS with 0.1% Tween. The
membranes were blocked with 5 mL of TBS with 5% BSA (pSMAD1/5, TFNR-1) or milk
(pSTAT3) with 0.1% Tween and 1:5000 dilution of secondary antibodies for 45 minutes at room
temperature. LICOR IRDye secondary antibodies, 680 RD Donkey Anti-Mouse (926-60872) and
800 CW Donkey Anti-Rabbit (926-32213), were used in this assay. The membranes were rinsed
3 times for 5 minutes with 5mL TBS and then imaged on LI-COR Odyssey® CLx imaging
software. The images were quantified using ImageStudio™ Lite from LI-COR.

Viability Assay: In vitro EC50 was determined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium bromide (MTT) assay, which evaluates cytotoxicity. Nelfinavir was
tested with a 12-dose EC50 regime starting at 1-5 μM and increasing to 75-100 μM at regular
intervals. DMSO was used as the MTT solvent. The resulting % Survival (relative to untreated
controls) was plotted in GraphPad Prism. EC50 values were determined using a sigmoidal doseresponse (variable slope) curve fit, with a bottom constraint of 0.

Flow Cytometry: Cells were rinsed 2x with PBS followed by an incubation in accutase. Cells
were collected and rinsed 3x in PBS. Following this treatment, cells were fixed in 2% methanol
free PFA (define PFA) for 15 minutes at 4C. Following this, cells were rinsed 3x in PBS and
permeabilized in 0.1% saponin for 20 min at room temperature. Then blocked with Fc block for
15 min followed by an incubation in the FPN (Novus 21502PE) antibody for 20 min at room
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temperature then rinsed 3x with PBS and analyzed on the Cytoflex. All treatments had 6
replicates with 20,000 events per sample.

Confocal Microscopy: Cells were seeded on coverslips and two days later were fixed with
methanol free 4% PFA in PBS for 10 min. Cells were permeabilized with 0.1% Triton X-100 (in
PBS). Cells were blocked using Seablock Blocking Buffer (ThermoFisher Scientific) at room
temperature for 1 h. Hepcidin primary antibodies (70R-6236 Fitzgerald) were diluted 1:300 in
blocking buffer (10% Seablock Blocking Buffer in PBS with 0.1% Tween) overnight at 4 °C.
Coverslips were washed 3 times with PBS, and then incubated with FITC secondary antibodies
at a 1:1000 dilution in blocking buffer for 1 h at room temperature. Cells were then washed 3
times with PBS and incubated with 1:300 PE conjugated FPN/SLC40A1conjugated (NBP121502PE) in blocking buffer overnight (PE). Cells were then washed 1 time with PBS followed
by a 5 min 4’,6-diamidino-2-phenylindole (DAPI) 0.1 μg/mL stain in blocking buffer. Coverslips
were then washed with PBS-T once followed by 2 washes with PBS. Coverslips were mounted
on slides using ProLong Diamond Antifade Mountant (ThermoFisher Scientific) and cured for
24 h before imaging. Imaging was performed using Leica TCS SP8 DMi8 confocal laser
microscope using the 40x oil immersion lens with the Leica Application Suite X software
version 3.1.1.15751 for collection of images and analysis. After the acquisition, images were
processed using Huygens Deconvolution and 3D analysis software 19.04.0p664b for quantitation
and colocalization analysis. Image channels were acquired sequentially using appropriate
settings for DAPI, PE, and FITC (Invitrogen, A-21126, 1:500).
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Furin Assay: MCF-7 and MCF-10a 96 well plates were seeded at 10,000 cells per well. Cells
were induced with various treatments for 24 hours. Method based on work of 117. The media is
removed and cells are washed three times with PBS followed by a resuspension in 100 μL of 5x
lysis buffer (500 mM HEPES, pH 7.0, 2.5% Triton X-100, 5 mM calcium chloride, 5 mM βmercaptoethanol). After incubating for 15 minutes in lysis buffer 20 μL was added to the
fluorescence compatible Perkin Elmer OptiPlate™-96F (6005270) along with 10 mM furin
substrate (Enzo Life Sciences Cat# ALX-260-040-M005) and milli-Q water for a total volume of
100 μL. Fluorescence was measured before addition of substrate and for 60 minutes after adding
substrate every 5 minutes on a Perkin Elmer Victor Nivo Multimode Plate using an excitation of
355/40nm and the emission of 460/30nm and the D400 dichroic mirror. A BCA was run for total
protein concentration on remaining lysis buffer.

Ferrozine Assay: Whole cells from a T-75 cell culture flask (Starstedt, Inc.) were placed on ice,
rinsed with PBS, and scraped into 15 mL conical vials (Starstedt, Inc.). Cells were centrifuged,
excess supernatant was removed, and approximately 50 µL PBS was added to each vial. Cells
were frozen in LN2 and stored at -80ºC. Cells were thawed and 260 µL of PBS was added to
each vial. Cells were lysed with 155 µL of 50mM Trace Metal Grade NaOH on a shaker in a
humidified atmosphere for 2 hours. The glassware used to make the 50mM NaOH and other
solutions was rinsed in Trace Metal Grade 12M HNO3 and Mili-Q water and dried in the oven at
50ºC. Cell lysate was stored at -20ºC. After thawing, 155 µL of an acid solution containing 0.6M
Trace Metal Grade HCl and 0.6M Ascorbic Acid solution were added to each vial. The vials
were heated at 60ºC in an oil bath in a fume hood for 2 hours. During this time, a standard curve
was made with a 2:1:1 ratio of stock Fe solution, 50mM NaOH and HCl/Ascorbic Acid solution.
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Stock Fe solution was made using Mohr’s Salt and Milli-Q water. The standard curve covered 01.4 ppm in 0.2 ppm increments and 0-14 ppm in 2 ppm increments. Samples were cooled to
room temperature and centrifuged to gather all liquid. The cell lysate samples, and standard
curve samples were then brought to a pH of 4-5 using NaOH as visualized using pH paper. 210
µL of each cell lysate and standard curve sample were added to a 96-well plate. Cell lysate
samples were done in triplicate while standard curve samples were done in duplicate. 70 µL of
the Iron-Chelating Reagent (6.5mM Ferrozine, 13.1mM Neocuproine, 5M Ammonium Acetate,
2M Ascorbic Acid) were added to each well. The plate was covered with parafilm and foil and
put on a shaker for 30 minutes at room temperature. The plate was read by a plate reader
(Synergy H4 Hybrid Reader,BioTek) for absorbance at 562 nm.

Real-time qPCR: RNA was isolated using a Micro Kit (cat# 74004) following the
manufacturer’s instructions. Samples were then quantified via fragment analysis for quantity and
purity. RNA samples were diluted to 10 ng/ml and 2.2 μL of diluted RNA was used with the
iTaq Universal SYBR Green One-Step Kit (Bio-Rad cat# 172-5151) with 320 nm primers total
volume was 18 μL. Three biological replicates were run in duplicate for each treatment. To make
standard curves, serial dilutions of RNA were added to the RT reaction. Samples were analyzed
on the Bio-Rad CFX96 RealTime PCR Detection System.

ELISA: Media was collected and frozen immediately to -80C. Cell lysates were scraped and
rinsed followed by three freeze thaw cycles from -80C to RT. Followed by centrifugation at 1500
RPM for 15 minutes. Media samples were also centrifuged at 1000 RPM for 15 minutes and
diluted 50:50 with sample diluent. BCA was performed on lysate samples. Hepcidin-25 ELISA
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kit (LSBio cat#LS-F40093) was used and the procedure was executed according to
manufacturer’s instructions.

2.4

Results

To investigate the mechanism used by tumorigenic cells to accumulate iron, we began by
investigating how cancer cells acquire iron. We measured TFR-1 levels as shown in Figure 2.2.
TFR-1 is present at much higher levels in the MCF-7 tumorigenic cell line when compared to the
non-tumorigenic MCF-10a cells. Secondly, we see that regardless of increased inflammatory
cytokine treatment or drug treatment the iron import protein is present at significantly higher
levels in the tumorigenic MCF-7 cell line. Elevated TFR-1 is consistent with the accumulation of
iron in cancer cells.
Since tumorigenic cells have elevated levels of the iron import protein TFNR-1, we
investigated whether they had more internalized iron via total iron content measurements using
the ferrozine assay. Results are shown in Figure 2.3. We see that the total levels of iron are
significantly higher in MCF-7 cells.
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Figure 2.2 Transferrin Receptor-1 Levels in MCF-7 and MCF-10a Cell Lines
A) Western blot using a 12% gel. Data comparing MCF-7 and MCF-10a lines with
various treatments. B) Lanes of MCF-7 lysates are quantified in graph below from
left to right: 1) normal growth conditions, 2) 10 ng/mL IL-6, 3) 20 ng/mL IL-6, 4)
10 ng/mL IL-6 + 10 μM Nelfinavir 5) 20 ng/mL IL-6 + 10 μM Nelfinavir, 6) 10
μM Nelfinavir. All cells were induced for 24 hours.

We postulated that the tumor cells accumulated iron for multiple reasons. The first is
caused by the elevated levels of TFR-1 that imports iron. However, tumor cells exist in elevated
inflammatory conditions where hepcidin is present, and we postulated that FPN might exist at
lower levels where iron export from cells would be inhibited. As mentioned earlier, the only iron
export protein and thus a key regulator in the iron export process is FPN. The goal of this work is
to determine if we can modulate FPN levels to regulate iron levels in cancer cells.
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Figure 2.3 Total Iron Levels in MCF-7 and
MCF-10A Cell Lines
Lysed cells were used to quantify total iron.
Results were normalized to protein content.
p<0.01 n=6

We first measured FPN levels with confocal microscopy. Figure 2.4 shows the results of
fluorescence imaging of FPN in the tumorigenic cells (MCF-7). MCF-7 cells were grown using
several conditions including normal media, the addition of inflammatory cytokines (10 ng/mL
IL-6 and 10 ng/mL BMP-9), 10 μM Nelfinavir as a control to evaluate Nelfinavir’s effect on
FPN and finally cells treated with a combination of inflammatory cytokines IL-6 and BMP-9 and
Nelfinavir. Our lab has previously demonstrated that Nelfinavir can inhibit hepcidin. We
postulated that Nelfinavir treatment would increase FPN on the surface of MCF-7 and MCF-10A
cells.
Figure 2.4 shows that FPN is present in MCF-7 cells in normal media. Treatment with
IL-6 and BMP-9 decreases FPN levels in these cells. 10 μM Nelfinavir treatment in normal
media shows FPN at intensities similar to cells grown in normal media. It is interesting to note
that Nelfinavir treatment appears to concentrate FPN on the membrane of the cells (Figure 2.4
third row). When MCF-7 cells treated with IL-6 and BMP-9 are also treated with 10 μM
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Nelfinavir, the FPN levels are similar or higher than in non-inflamed MCF-7 cells. This indicates
that Nelfinavir can maintain FPN on the surface of the cells.
Prohepcidin

Ferroportin

Merge

IL-6 BMP-6 & 10
μM Nelfinavir

10 μM Nelfinavir

IL-6 BMP-6

Control

DAPI

Figure 2.4 Confocal Microscopy Images of MCF-7 2D
Cell Culture
Cells were treated for 24 hours with corresponding treatments:
Top Row, normal growth media, Second Row, 10 ng/mL IL-6
and 10 ng/mL of BMP-6, Third Row, 10 μM Nelfinavir and
control media, Fourth Row, 10 ng/mL IL-6 and 10 ng/mL of
BMP-6, with 10 μM Nelfinavir. Green represents Prohepcidin, Red represent FPN, Blue represents DAPI.

We also compared FPN levels in MCF-7 cells and MCF-10A cells, the non-tumorigenic
control cells in these studies. Analysis of this data showed that FPN levels were logarithmically
lower than the non-tumorigenic cell lines (MCF-10A).
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To this point, our data has shown that MCF-7 cells have elevated iron levels compared to
MCF-10A cells. The elevated levels of TFR-1 and decreased levels of FPN account for increased
uptake of iron and decreased iron export. Nelfinavir treatment also showed stabilization of FPN
in MCF-7 cells. Our overall goals are to treat the tumor cells with Nelfinavir to ultimately
stabilize FPN and release iron sequestered in cells. To fully understand the effect of Nelfinavir
on the cells we need to understand viability of the different cell lines with Nelfinavir treatment.
We investigated the IC50 of Nelfinavir in MCF-7 and MCF-10a cell lines. We performed
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) cell viability
experiment to determine the IC50 and or toxicity of Nelfinavir in each cell line. As we see in
Figure 2.5 the tumorigenic MCF-7 cells are more sensitive to Nelfinavir treatment. The IC50 in
the MCF-7 tumorigenic cells was 9 μM and 22 μM in the MCF-10A non-tumorigenic cells.
Although our goal is to lower hepcidin, the fact that the tumor cells are less viable with nelfinavir
treatment is an important side benefit that may slow cancer growth. This shows that we can use a
lower dose of Nelfinavir that can target the tumor cells while mitigating damage to healthy cells.
As mentioned above, Figure 2.4 shows FPN in images of inflamed, inflamed treated, and
treated control samples. It is important to note that we were measuring prohepcidin levels. The
active form Hepcidin-25 is more rapidly excreted from the cell and would not be present in
sufficient levels inside the cell. We see that Nelfinavir treatment alone is correlated with a
decrease in prohepcidin and that Nelfinavir with inflammation increases prohepcidin levels.
Based on our model we would expect prohepcidin levels to build up when furin was inactivated.
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We see increased FPN levels in red when treated with 10 μM Nelfinavir in the presence of
inflammation. These images are the result of one biological replicate. More imaging experiments
are underway to confirm with statistics.

Figure 2.5 Nelfinavir Dose Response and IC50 Values for MCF-7 and MCF10a Cell Lines.
Nelinavir toxicity was evaluated on both the tumorigenic and non-tumorigenic cell
lines. Results suggest that tumorigenic cells are much more susceptible to
Nelfinavir treatment than non-tumorigenic cells.

In complement to this experiment, we ran flow cytometry experiments to quantify the
amount of FPN on each cell type (Figure 2.6). We verified that FPN was indeed sensitive to
hepcidin regulation by including a hepcidin induced control. In treated MCF-10a cells FPN
decreases in response to elevated hepcidin-25 levels. This however was not the case for the
MCF-7 cell line. They showed an insignificant response to hepcidin-25 treatment. We also have
included an isotype control for another measure of FPN antibody specificity. It seems that the
antibody bound more strongly to FPN on the MCF-7 cell lines than the MCF-10a cell lines. We
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draw this conclusion from comparing the isotype control levels. This makes it difficult for us to
compare FPN levels from different cell lines. It seems that Nelfinavir treatment significantly
increases the amount of FPN in the cancer cells.

MCF-7

MCF-10a

Figure 2.6 Flow Cytometry Ferroportin Levels
Cells were treated for 24 hours with the indicated treatments. Cells were fixed
with 2% PFA permeabilized with 0.01% saponin and blocked with human Fc
block prior to incubation with FPN antibody. P values were calculated using an
ordinary one-way anova. n=6 replicates for each treatment. P<0.04=*,
P<0.01=**, P=0.006=***, P<0.0001=****.
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Hepcidin-25 Levels
in MCF-7 Cells

Figure 2.7 Hepcidin-25 ELISA
MCF-7 cells were treated with the indicated
treatment for 24 hours with various
treatments. Media from the cells (n=3) was
tested for Hepcidin by ELISA. P values
were calculated using an ordinary one-way
anova. n=3 replicates for each treatment.
P<0.03=*, P=0.0001=***, P<0.0001=****.

Our next question was to validate that increased hepcidin-25 activation by furin was the
cause for FPN protein levels being lower. It is well established that hepcidin-25 binds to FPN
and degrades it. Based on that assumption we hypothesize that levels of hepcidin-25 should be
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higher in the tumorigenic cells (MCF-7) and lower when treated with Nelfinavir. We grew MCF7 cells and treated them with different concentrations of Nelfinavir and with inflammatory
cytokines with and without Nelfinavir. We investigated total levels of Hepcidin-25 secreted into
the media using an ELISA. MCF-10A cells were also treated identically and Hepcidin-25
measured, and these cells responded in a similar fashion as the MCF-7 cells (data not shown).
Results show a dose response of decreasing hepcidin-25 in the media with increasing Nelfinavir
concentration treatment in cells grown in normal media and in cells treated with inflammatory
cytokines (Figure 2.7).

Figure 2.8 Furin Assay Procedure.
Cells were grown in a 96 well plate and induced with various treatments for 24
hours. Following this they were lysed and a furin consensus substrate was
added. When the substrate is cleaved by furin it then allows for its probe 7amino-4-methylcoumarin to fluoresce. The more fluorescence the more active
the furin. The fluorescence is measured over time to observe the rate of furin’s
activity.
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Next, we investigated the potential mode of action for Nelfinavir stabilizing FPN through
furin activity inhibition. Our lab has previously demonstrated that Nelfinavir is a furin
inhibitor118. These docking studies showed promising binding activities however these had not
been tested in vitro or in vivo. We were able to use the furin assay to evaluate the efficacy of
Nelfinavir for inhibiting furin. As shown in Figure 2.8 the furin assay is a fluorogenic assay
where a peptide with the furin cut sequence is attached to a fluorescent marker. Upon cleavage of
the peptide by furin, the fluorophore is released and becomes fluorescent.
We studied furin enzyme activity in tumorigenic (MCF-7) and non-tumorigenic (MCF10a) cell lysates from cells grown under a variety of inflammatory and Nelfinavir treated
conditions. Our results in Figure 2.9 shows that 15 μM Nelfinavir has similar inhibition
properties against Furin as 10 μM CMK, a known furin inhibitor. Interestingly cells that are
inflamed seem to have lower levels of furin activity which was unexpected especially as furin is
typically elevated with inflammation118. This data show that furin plays a significant role in
regulating the FPN/hepcidin axis and that Nelfinavir treatment can inhibit the activation of
hepcidin-25.

Next we were interested to see if it may be due to some genetic regulation. We performed
qPCR analysis on various treatment groups as shown in Figure 2.10. We see that Nelfinavir
treatment is shown to significantly increase furin expression in MCF-7 cell line. It is important to
note that all other differences are statically insignificant.
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Figure 2.9 Furin Activity of MCF-7 and MCF-10a Cell Lines
Cells were treated with the indicated treatment for 24 hours. After the 24-hour treatment,
the cells were lysed, and cell lysates were tested for furin enzyme activity. In A and B, we
see the effect of Nelfinavir treatments on cells grown under normal conditions (controls). In
C and D, the furin enzyme activity is shown for inflamed cells treated with 10 ng/mL IL-6
and BMP-6 and 10 μM Nelfinavir. E and F show the comparisons of the slopes of the
kinetic graphs in A-D. P values were calculated using an ordinary one-way anova. n=3
replicates for each treatment. P<0.03=*, P=0.0001=***, P<0.0001=****.
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Figure 2.10 qPCR Results for 2D Cell Culture Treatments.
qPCR was performed on n=3 replicates. An unpaired t-test was used to produce listed p
value. All other differences were statistically insignificant.

Using MCF-10a and MCF-7 cell lines we were able to produce viable 3D spheroids
according to methods outlined. Images shown in Figure 2.11 are taken at the same magnification
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to show the difference in structure. The use of such models has shown to have increased
signalling pathways that can better mimic the tumor or tissue microenvironment.75, 89

Figure 2.11 3D and 2D Cell Culture Images
We investigated the inflammatory signalling and iron regulatory differences in the
tumorigenic and non-tumorigenic cell lines. We see elevated levels of iron in the cells in the 3D
culture as shown in Figure 2.12. We also see that with Nelfinavir treatment, has a trend of
lowering iron content in the cells, however changes are not statistically significant. We propose
that the release of iron is due to FPN stabilization.
We were able to investigate the differences in mRNA levels of hepcidin mRNA, FPN
mRNA and Furin mRNA between 2D and 3D cell cultures of MCF-7 and MCF-10A. In each
comparison of cells, the mRNA levels were lower in the 3DF cultures than the 2D cultures. It
seems that furin mRNA (Figure 2.13) is much higher in theMCF-10A cells than in the MCF-7
cancer cells. More research needs to be done to investigate the role of furin, Hepcdin-25, and
FPN in 3D cells. It may be that these signalling pathways are exacerbated like the iron findings.
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2.5

Discussion
Nelfinavir IC50 values range from 8-17 µM in various leukaemia cell lines.119 In our

studies we found the IC50 to be at 9 µM which would be on the lower end of the range making it
an option in breast cancer treatment. Nelfinavir has shown to have several anti-cancer effects
such as the inhibition of E-cadherin and MMPs that are critical for metastasis and tumor
growth.84, 116 It has also been shown to inhibit drug metabolism pathways. Studies have
investigated using Nelfinavir as a chemosensitizer in combination with other chemotherapeutics
like Doxorubicin and Tamoxifen.81, 116

Figure 2.12 Total Iron in 2D vs 3D Cell Culture
All cells were treated for 24 hours followed by iron quantification via ferrozine
analysis. In A we see differences between iron levels in 2D and 3D as well as nontumorigenic and tumorigenic cells. In B and C results show differences between
treatment groups. n≥5 for each treatment group
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Nelfinavir was able to significantly stabilize FPN levels as shown in Figure 2.4 and
Figure 2.6 through the mitigation of hepcidin-25 activation as shown in Figure 2.7. Hepcidin-25
levels decreased in a dose dependent manner when treated with Nelfinavir. We also saw that
Nelfinavir was able to help in rescuing inflamed cells. FPN has been a particularly difficult
protein to quantify. Our lab has spent significant resources in implementing new quantification
techniques for FPN. Flow cytometry has been the gold standard for our lab, but this technique
makes it difficult to compare protein levels between cell lines due to different antibody binding
interactions. In our study we used an isotype control to illustrate the difference of this binding
between the two cell lines. Ideally western blotting or mass spectrometry would be a more

Figure 2.13 Differences in mRNA Levels Between 2D and 3D cells
Control lysates from each type were compared with n=3 replicates. There was no
significant difference between cell types.

definitive way to quantify total protein between both cell lines. Hepcidin-25 is another difficult
to probe protein due to its small size and presence in inactive precursors as shown in Figure 1.4.
Antibody selectivity is critical when probing for hepcidin-25. In our imaging studies we chose to
probe for prohepcidin as it is known to be excreted at a slower rate than hepcidin-25.24 We also
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hypothesize that pro-hepcidin will increase in concentration when furin activity is inhibited
because it will remain uncut. We see this occurring in Figure 2.4 where nelfinavir treatment
increases the prohepcidin signal. We see that a majority of this prohepcidin seems to localize at
or near the nucleus. It is known the prohepcidin binds in the nucleus to regulate its own mRNA
expression.31
It seems that the effect of Nelfinavir on FPN does show an emerging trend of lower iron
however iron levels were not to a statistically significant level when FPN was stabilized with
Nelfinavir. This may be due to the fact that fluctuations in iron levels are very small over the
course of a 24-hour period. Longer induction times should be investigated to see if the
stabilization of FPN can induce a significant decrease in iron stores. Nelfinavir is known to
induce autophagy and apoptosis. It is possible that iron is being used to promote a process
similar to ferroptosis. More investigations need to be done to understand what role iron is
playing in Nelfinavir treatment. It seems that if this were the case it would make Nelfinavir
treatment even more selective as it would be more deadly for tumors known to sequester iron
than healthy tissues deficient in iron.
Nelfinavir was shown via docking studies to be a suitable target for furin inhibition.118
Our findings support this hypothesis as we see in Figure 2.9A and B that Furin activity is
significantly lowered with the treatment of Nelfinavir. It is particularly interesting that the
inhibition of furin is as effective as the known furin inhibitor-1 CMK. Currently there are no
FDA approved Furin inhibitors. Nelfinavir has been FDA approved for more than two decades
with manageable side effects. The repurposing of Nelfinavir as a Furin inhibitor is intriguing
because furin has many targets other than hepcidin.
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We see some interesting findings in Figure 2.9C where inflammation seems to lower
furin activity. It has been shown that IL-6 can inhibit MCF-7 cell proliferation when expressed in
high levels (~100 nM). In our study we induced with IL-6 levels near 0.3 nM.120 This could have
played some role in furin inhibition. Previous studies have found that IL-6 downregulates MMP2/9 mRNA levels which are also known furin targets. More studies should be done to understand
the interplay between furin and the many cytokines that influence its regulation including IL-6.
IL-6 and BMP-6 were endogenously added to mimic a more realistic tumor
microenvironment based on the work of Blanchette.37, 89 Our 3D Models mimic these signalling
pathways in a more realistic way. Ideally, in the future we would prepare the 3D cultures with
fibroblasts and other cell types to enhance the tumor microenvironment. Although 3D cells
models provide a much better model for drug evaluation, they are difficult to test. We ran into
issues with cell differentiation in flow cytometry thus preventing us from being able to clearly
define cell populations. 3D imaging is a difficult skill and was not able to be achieved in the time
frame we had to work with. This resulted in only being able to produce total iron level data. We
see that indeed the 3D cells sequester much more iron than the 2D cells. We have some
supplementary data that illustrates the increased signalling pathways of BMP-6 and IL-6 in the
3D model. Future work would include a full evaluation of the iron regulatory pathways involved
in iron sequestration and regulation.
Our qPCR data in Figure 2.10 showed insignificant differences in HAMP and slc40a1 but
a significant increase in Furin. This may be due to promoter binding proteins that require furin
activity for maturation as mentioned in the introduction. The insignificant differences in gene
expression with treatment further support the hypothesis that Nelfinavir inhibits furin activity
post translationally. In Figure 2.13 showed an insignificant difference between 3D and 2D
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mRNA levels of HAMP, slc40a, and fur. Previously Blanchette et al.75 found HAMP levels in
3D cell lysates to have significantly higher levels of HAMP mRNA. This difference could be due
to different 3D growth procedures, primer efficiencies, or other experimental conditions.

2.6

Conclusion
More work needs to be done to understand the role of furin inhibition on anemia of

cancer. Nelfinavir is a selective and anti-tumorigenic option. Our studies indicate that Nelfinavir
does significantly inhibit Hepcidin-25 activation and stabilize FPN through Nelfinavir inhibition
of furin. These novel findings connecting furin to key iron regulatory proteins in the
hepcidin/FPN axis suggest the need for further studies. Understanding the nuances of furin may
lead to understanding the nuances of anemia in chronic diseases such as cancer.
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Appendix A. Investigation of Anemia in a High Fat High Sugar Diet in Wistar Rats
Naomi Flindt, Steve Christiansen, Brandon Rose, Roger Woolley, Alexis Gardner, Annie Taylor,
Paulina Medellin, Jacob Parker, Grant Flindt, Ellis Truman, Cade Nordhagen, Kirsten Flindt,
Grant Balls, David Kooyman, Richard Watt
A.1

Abstract
The western diet has been shown to have many deleterious effects on health as the

inflammatory stimulus can often perpetuate and sometimes initiate disease. It has been shown
that a high fat high sugar diet can induce diabetes mellitus and osteoarthritis. These
inflammatory induced diseases are often accompanied by anemic conditions. In this study we
investigate the effects of a protease inhibitor Nelfinavir on the inhibition of arthritis and anemia
pathways. Nelfinavir has been shown to inhibit furin is a protease known to activate matrix
remodeling proteins (MMPs) and facilitate cartilage build up. Furin is also known to inhibit other
iron sensing pathways and can potentially treat anemia which is commonly prevalent in diabetic
patients. We investigated the effects of 30 days of Nelfinavir treatment on Wistar rats. We were
able to collect complete blood counts (CBC), total iron levels by organ, glucose testing, and
arthritis scoring. It seems that the high fat high sugar rats did not develop significant anemic
symptoms in comparison to the control rats. Based on our results Nelfinavir seemed to develop a
more severe anemic conditions as well as intensify arthritic conditions.

A.2

Introduction
Diet induced inflammation has been shown to upregulate inflammation causing a host of

chronic disease comorbidities including: arthritis, diabetes mellitus, fatty liver disease, CKD and
Fibrosis.67, 121, 122 Diets high in fats and sugars have been associated with causing inflammation.
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These inflammatory diseases are often found to have higher levels of furin.123 Furin is potentially
upregulated via the IL-6 and BMP-6 same pathways outlined in Chapter 1. High furin expressing
pancreatic cells have low insulin but fast growth while low expressing cell lines have slow
growth and larger pools of insulin.124 SREBP-1c transduces the insulin signal and induces
expression of glucose utilization and fatty acid synthesis.125 In addition to increased metabolic
utilization, inflammatory diseases are often correlated with a 25-30% increase in the rate of
lipogenesis and oxidative stress in the liver.125 Increased matrix remodeling via furin mediated
MMP activation is another oxidative stress driver prevalent in arthritis.78, 96, 101, 126 Increased
oxidative stress, when chronic, can deplete protective antioxidants leading to an increase in
unchaperoned iron and deleterious effects of radical oxygen species (ROS). ROS lead to anemia
through damaging erythrocytes and decreasing available iron for erythropoiesis by upregulating
hepcidin thus perpetuating ROS and disease progression.122
Treatment options for anemia of chronic disease are nuanced as discussed in chapter one.
It has been shown that many standard therapies such as ESA are correlated with adverse
cardiovascular events.74 In another study they used anti-hepcidin treatments to address the
inflammation first by decreasing hepcidin levels. This treatment led to reduced iron in
macrophages and a decrease in foam cell formation and atherosclerosis.60 Thus, implying a
strategy that can mitigate hepcidin-25 activation while also stabilizing FPN has potential to treat
anemia of chronic inflammation. Nelfinavir an FDA approved pro-protein convertase has been
shown to inhibit hepcidin levels in HepG2 cells as well as a previous LPS inflamed Lewis rat
study.118 In addition to Nelfinavir mitigating Hepcdin-25 activation it has potent antiinflammatory effects as it inhibits furin. Since furin is an integrated inflammatory cytokine
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processor, targeting it can potentially mitigate MMP activation among other inflammatory
mechanisms that drive disease progression.
In this study we seek to inhibit arthritis progression via Nelfinavir induced furin
inhibition while also alleviating anemia of chronic disease. We plan to investigate changes in
metal localization with the upregulation of related metalloproteins and their potential protective
effects on chronic inflammation. These aims collectively will aid in understanding how hepcidin
regulates the localization of various metals during inflammation in an in vivo model. This is an
important step in understanding the role that metals play in the pathogenesis of inflammation and
related diseases such as diabetes, and arthritis.

A.3

Methods

Animals: were maintained in a humane manner following IACUC guidelines and protocols.
Animals were obtained from Jackson Labs. We used a high-fat, high-sugar (HFHS) diet
comprising TD.08811 (Envigo) and 25% fructose in double-distilled sterilized drinking water
and allowed to consume these diets ad libitum for 4 weeks; the control groups received a
standard rat chow (SC) comprising LabDiet 5001 (LabDiet) and distilled drinking water. Our
choice of this regimen was based on a proprietary diet used in a previous publication.121 16
Lewis Rats were raised on a HFHS sugar diet for the last 16 weeks of their life. The other 16 rats
were raised on a control diet for the entire study. 8 male HFHS rats, 8 male control, 8 female
HFHS, and 8 female controls. Four rats in each group were treated and the other four received a
vehicle control treatment. Except for 3 females in the nelfinavir treated HFHS and 3 males in the
nelfinavir treated HFHS males. Treatment began at 49 weeks. The HFHS rats had been on a
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HFHS diet for 16 weeks prior to the beginning of treatment. One of the nelfinavir treated female
HFHS rats had a tumour and data has been omitted. Another nelfinavir treated HFHS male rat
was severely immunocompromised and died shortly after treatment began. Treatment was
administered via intraperitoneal (IP) injection twice daily for 30 days. Rats were dosed at 18
mg/kg. Females received a 1.8 mL injection, males received a 3.2 mL injection of a 4 mg/mL
solution of Nelfinavir in 5% DMSO 5% PEG-400 and 5% Tween-80 with sodium chloride.
Nelfinavir was extracted in DMSO from crushed 625 mg Viracept® pills (Agouron
Pharmaceuticals ndc 63010-027-70) with ~95% efficiency. Nelfinavir was quantified using
HPLC prior to dilution for injection based on the methods of Charbe et al.127 Vehicle control rats
were injected with equal volumes of a 5% DMSO 5%PEG-400 and 5%Tween 80 with sodium
chloride based on the methods of Gassart et al.128 Dissection was performed under anaesthesia
via cardiac exsanguination.
Pain assessment in rats employed the Brigham Young University rodent pain assessment
Standard Operating Procedure (SOP) developed by the University Veterinarian, based upon
American Veterinary Medical Association (AVMA) guidelines and approved by the University
IACUC.

Blood Tests: Blood was taken the day before the first day of treatment and at day 14 and at
dissection. 1-1.5 mL of blood per draw via tail vein. Blood was collected in lithium heparin and
EDTA tubes following the order of draw. Blood was kept on ice. EDTA tubes were used for
CBC analysis at Utah Valley Hospital and blood smears for a differential, reticulocyte count, and
abnormal morphology scoring.
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Morphology Scoring: Blood smears were fixed with methanol and stained with Wright’s Stain
(Electron Microscopy Sciences Cat# 26060) following manufacturer instructions. This allows
visibility of white blood cells for differentiation. It also allows a clear view of red blood cell
morphology which can be indicative of anemia status. Red Blood Cell Morphology was graded
on a scale of 1-3 dependent on the number of event type found in the sample. 10 replicates per
sample were counted.

Insulin Tolerance Test: Four days prior to euthanasia, were performed on day 27 of treatment to
determine the effect of the HFHS diet and/or Nelfinavir on insulin responsiveness. Animals were
fasted for six hours’ time (6:00 A.M.-12:00 P.M.), receiving only distilled water during that
span. Blood glucose was measured using a Contour 7151H Glucometer and 7097C test strips
(Bayer) immediately before injection of insulin (fasting blood glucose) as well as at time points
15, 30, 60, 90, and 120 minutes after insulin injection. Novolin R (Novo Nordisk Medical) was
diluted in 1X PBS (Fisher Scientific BP399-500) to a concentration of 0.75 IU/mL and
administered IP at a dosage of 0.75 IU/kg. Following the cessation of ITT, animals resumed
assigned diets and drinking fluids.

Flow Cytometry Erythropoiesis: was monitored using Bone marrow cells were filtered then
blocked using Rat Fc Block from BD followed by staining with CD45 and HIS49 for 20 minutes
on ice. Cells were then washed 3x prior to analysis. CD44 conjugated to FITC and HIS49
conjugated to APC. Gating strategy included gating for healthy cells, single cells, HIS49 positive
cell, and finally a scatter plot of SSC vs CD44.

62

Flow Cytometry Ferroportin/Macrophage: Tissues were collected in PBS, digested, and red
blood cell lysed using RBC lysis buffer for two minutes. This was followed by 3 rinses in PBS
and an accutase digestion for 1 hr at 37C. Following this samples were filtered and washed 3x.
Then cells were fixed in 1% methanol free PFA for 15 min on ice followed by permeabilization
in 0.1% saponin for 20 min on ice. Following this samples were blocked for 15 min on ice and
then stained and washed 3x prior to analysis. Single and unstained controls were also accounted
for. Samples stained with CD45 were blocked and stained prior to fixation/permeabilization then
the other stains were used. FPN NBP1-21502 from Novus conjugated to PE, CD45 conjugated to
APC-A750, CD68 conjugated to PerCP, CD163 conjugated to Pacific Blue.

ELISA: Hepcidin-25 ELISA was acquired from LS-Bio (Cat # LS-F56097). Aliquoted serum
samples were quantified for protein content. Samples were then normalized and ran according to
manufacturer instructions.

Microscopy: Tissue was immediately immersed in 4% PFA for 24 hours at 4C followed by
sucrose cryopreservation using a 15% sucrose solution for 24 hours followed by a 30% sucrose
solution for 24 hours before being trimmed and cryo-embedded into tissue Tek OCT.

Histology: Tissue was immediately immersed in 4% PFA for 24 hours at 4C followed by sucrose
cryopreservation using a 15% sucrose solution for 24 hours followed by a 30% sucrose solution
for 24 hours before being trimmed and cryo-embedded into tissue Tek OCT.

qPCR: Tissue was snap frozen and stored at -80C until ready for RNA extraction.
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ICP-MS: Tissue was snap frozen and stored at -80C until ready for nitric acid digestion. Frozen
samples were crushed, weighed, and suspended in trace metal grade HNO3 at 100 mg/mL.
Samples were sealed and digested at 65°C overnight. Following this samples were centrifuged
and 50μLof digested sample were diluted to 5 mL in Milli-Q water. Chromium was added as an
internal standard. Samples were filtered using a 0.45 μm PES filter prior to analysis.

A.4

Results & Discussion

CBC Data

Complete Blood Count (CBC) data is an important diagnostic tool used in assessing
anemia. We were able to run CBC samples prior to starting treatment. Two weeks into treatment
and at 4 weeks of treatment. The two tables provided show interesting comparisons between
different treatment groups. In Table A.1 the top table shows that the high fat high sugar female
rats did not have a significant decrease in haematocrit when on the HFHS diet. However, males
on the HFHS diet had a significant decrease Hb, haematocrit, red blood cell count and white
blood cell counts. It also seemed that the male rats receiving Nelfinavir treatment had a decrease
in iron parameters leading to an increased anemic phenotype. These changes in CBC parameters
seem to suggest a very slight decrease that may not be clinically apparent. Additionally, it is
interesting to see a decrease of all blood cell types (white and red). This is typically not the case
for anemic patients. Table A.2 lists additional comparisons for the HFHS diet rats. Table A.3
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lists the additional comparisons for control diet rats. These additional comparisons help to aid as
controls.

Erythropoiesis

Bone marrow samples were stained for erythrocyte progenitors. This experiment was
critical in understanding the influence of Nelfinavir on erythropoiesis. The graphs in Figure A.1
show the changes in erythrocyte maturation. We see that with Nelfinavir treatment we have an
increased amount of Reticulocytes however not an increased amount of total red blood cells.
This data suggests that Nelfinavir may be inhibiting erythropoiesis. This would also explain the
decrease observed in all blood cell types form the CBC data.

Arthritis Scoring

Mankin scoring was performed using a stain and scoring system. It seems that all the rats
were in the arthritic region and Nelfinavir treatment seemed to increase the severity of arthritis
score however this increase was not statistically significant. Results are shown in Figure A.2.
Because Nelfinavir has been shown to inhibit matrix remodeling proteins these results were
surprising. More work needs to be done to understand the specific activity of furin on MMPs as
well as what affect Nelfinavir may have on their activity.

Glucose Intolerance
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Glucose intolerance seemed to be more prevalent in the high fat high sugar rats. Results
are shown in Figure A.3. It has been shown that glucose intolerance can be induced by a HFHS
diet121. It seems that our rats had similar glucose profiles regardless of diet and Nelfinavir
treatment.

Hepcidn-25 Expression Levels in Serum

Hepcidin-25 levels in serum after four weeks of treatment were measured using an
ELISA kit. The results did not seem to correlate as expected as shown in Figure A.4. We see that
the Male rats on both diets as well as female control rats seemed to have a slight increase in
hepcidin-25 with Nelfinavir treatment however, this increase is statistically insignificant. The
female HFHS rats did show a decrease in hepcidin levels with Nelfinavir treatment.

Iron localization by Organ

Iron levels were measured in the liver, spleen, and lungs. Iron levels were significantly
lowered in the liver in response to Nelfinavir treatment as shown in Figure A.5. These results
suggest that Nelfinavir is potent at releasing iron stored up in the liver back into the bloodstream.
Interestingly, Nelfinavir seemed to have the opposite effect on the liver and spleen. When rats
were treated with Nelfinavir spleen and lung concentrations increased. This increase was not
significant.

Ferroportin Expression in Activated Macrophages
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FPN levels on activated macrophages were measured using flow cytometry. The results
in Figure A.6.show an increase in FPN with Nelfinavir treatment. This increase was significantly
higher in the female rats as shown in. This data confirms that activated macrophages key in
erythrocyte recycling were able to release iron back into plasma when treated with Nelfinavir.
This is an important step in alleviating anemia.

A.5

Conclusions
This study It seems that there were several important parameters such as arthritis scoring,

hepcidin-25 levels and anemia data form the CBCs that were unexpected. It seems that this
model of inducing anemia did not occur. This may be due to the short amount of treatment.
Additionally, Nelfinavir had some interesting effect on erythropoiesis. More studies need to be
done to confirm whether Nelfinavir is inhibiting erythropoiesis. Some positive effects of
Nelfinavir include its ability to release iron from key bodily iron stores like the liver and
macrophages. This is an important in treating anemia of chronic inflammation. We are looking
into testing combination treatments of ESAs with Nelfinavir to induce erythropoiesis while also
releasing iron to facilitate erythropoiesis. Additionally, other protease inhibitors may be more
suitable targets that can continue to release iron from liver and macrophages while not inhibiting
erythropoiesis. We are looking into new ways to screen our protease inhibitors for the inhibition
of furin while not inhibiting erythropoiesis targets. Other PCs and concentrations should be
investigated for their concentrations.
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Table A.1 CBC Results for Control vs. HFHS Diet Comparisons
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Table A.2 CBC Results-for HFHS Diet
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Table A.3 CBC Results and Comparisons for Control Diet Rats
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Nelfinavir

Male

Female

Control

Figure A.1 Erythropoiesis Maturation in Bone Marrow
Erythrocyte maturation was monitored by using a series of cell
markers. FSC-A stands for forward scatter area. Cells scattered
farther to the right on the FSC-A axis are more granular. FITC-A is
the probe for CD-44 antibody. CD-44 is a marker for Erythocyte
maturation. Cells expressing lower levels of CD-44 are more
mature. Categories of eryhtrocyte progenitors displayed in graphs
are 1-Proerythroblast 2-basophilic ertyhroblast, 3-polychromatic
erythroblast, 4-orthochromatic erythroblast, 5-polychromatic
erythrocyte, 6-erythrocyte. The more red the higher the density of
cells. In the top left graph we are looking at the scattering of
erythrocyte progenitors in a representative replicate for female
control rat receiving vehicle. In the top right we see the Nelfinavir
treated female control rat. In the bottom left vehicle control male
rat. In the bottom right the Nelfinavir treated male rat.
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Figure A.2 Mankin Scores
Mankin scores are indicative of arthritis. A score of 5 or above is considered arthritic
and above 8 is considered osteoarthritic
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Figure A.3 Insulin Tolerance
Test rats were injected with insulin and glucose concentrations were monitored over the course
of 120 minutes. Some rats were severely affected and we released them early sue to sever
hypoglycemic shock symptoms.
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Figure A.4 Hepcidin-25 Levels in Serum After 30
Days of Treatment
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% of M1 cells expressing FPN

Figure A.6 ICP-MS Data for the Liver, Spleen, and Lungs
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Figure A.5 FPN Expression on
M1 Macrophages in the Bone
Marrow
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Appendix B. pXRF Quantification of Lateral Flow Immunoassays
Naomi Flindt, Annie Armitstead, Lara Grether, M. Jill Clapperton, Bruce Kaiser, Richard Watt
B.1

Abstract
New solutions for rapid and sensitive point of care testing have been required since the

beginning of the COVID-19 pandemic. The pandemic caused broad challenges for rapid
diagnostic testing that include issues from supply chain and limited material availability to
technology limitations such as the inability to detect and notify individuals of infection status at
the earliest times of infection. We developed and evaluated the use of cost-effective printer paper
Lateral Flow Immunoassay (LFI) tests that can be constructed when supply lines cannot provide
materials to construct LFI tests. We also evaluated portable x-ray fluorimeter (pXRF) as a reader
to quantify LFI results. To maximize LFI quantitation using pXRF, we created background
clearing chase buffers and wash steps to increase visualization of the test and control lines. When
using pXRF limits of detection were increased by 100-fold for common hCG LFI tests.

B.2

Introduction
The Covid-19 pandemic infused the rapid diagnostic field with motivation to create rapid

Covid-19 tests for early detection of the SARS-CoV-2 virus. The goal of virus testing is to detect
viruses like SARS-CoV-2 at the earliest stages of infection. A positive test result informs an
infected individual to quarantine to prevent spreading Covid-19. Rapid testing coupled with
efficient trace contacting, has the potential to inform contagious individuals to quarantine and slow
the progress of an epidemic or pandemic. To successfully battle a viral pandemic, tests need to
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detect the virus at low viral counts and as early in the infection as possible. With proper tests,
contagious individuals can quarantine, and the spread of a virus can be limited
During the early stages of the Covid-19 pandemic, Polymerase Chain Reaction (PCR)
testing was the gold standard because PCR testing identified SARS-CoV-2 mRNA at very low
levels and early in the infection. Several drawbacks hindered PCR testing during the early stages
of the Covid-19 pandemic. These challenges included problems with obtaining PCR supplies,
faulty tests and extended delays for patients receiving results of the tests129. These delays in
informing infected individuals that they were contagious allowed the virus to spread.
Antigen tests or lateral flow immunoassays (LFIs) do not have the low detection limit of
PCR but are cheaper to make and distribute and give results in less than 30 minutes. Since LFI
tests directly measure elevations in the viral load, virus detection by LFI tests correlates with the
contagious stage of viral infection. In the work of Mina et al.130 and Paltiel et al.130 the authors
modeled test sensitivity, selectivity and cost. Both groups conclude that frequent testing with lower
sensitivity LFI tests and strict behavioral interventions provides the most effective and economical
strategy for controlling viral outbreaks.
Another study by Larremore et al.131 was able to show that the more sensitive PCR tests
given frequently showed a marginal benefit in controlling the spread of the virus, but the cost and
delayed reporting might not justify the benefit. From these studies we learn that an ideal test will
have a low detection limit like PCR and give rapid results at low cost that allow increased
frequency of testing, like the LFI tests.
An additional challenge faced during the Covid-19 pandemic were disrupted supply lines
caused when countries shut down during the pandemic. Additionally, a surge to produce LFI tests
for the Covid-19 pandemic, depleted the sources of nitrocellulose, absorbance, conjugate, and
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sample pads as well as other required supplies for LFI tests. To address this challenge, our group
developed methods to create simplified LFI tests using printer paper. These simplified tests did
not require any of the normal absorbance, conjugate or sample pads associated with LFI tests.
These simplified tests can allow the preparation of LFI tests for pandemic testing if supply lines
were slow or inaccessible. We have named the in house tests the simple empowering LFI or
seLFI132.
Most at home LFI tests use a visible qualitative readout typically visualized using gold
nanoparticles (AuNP) conjugated to an antibody that binds specifically to the biomarker of interest.
If the biomarker is present, it will bind to the antibody and as it migrates through the test it will
bind to the test line antibody bound to the paper. The resulting sandwich of the biomarker between
two antibodies with the attached AuNP gives a red line at the test line (Figure B.1). A second
control line is made by attaching an antibody that recognizes the Fc domain of the AuNP
conjugated gold nanoparticle. This is known as the control line and indicates that the test ran
properly. The intensity of the red color of the test line is dependent on the amount of antigen
present. If low amounts of antigen are present in the sample, the test line may be too faint to see,
leading to a false negative. This has been a common issue during the COVID-19 pandemic when
tests are taken early in the infection stage when the viral load is not sufficient to give a positive
test line133, 134.
When the intensity of the test and control lines is below the visible detection limit, LFI
readers can be used to determine if the antigen is present. LFI readers commonly quantify
fluorescently tagged antibodies on the test strip. Fluorescence detection allows for quantitative
detection, and some fluorescence tags provide a degree of signal enhancement. Using LFI readers
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Figure B.1 seLFI Schematic
Simple empowering LFIs were made using functionalized paper attached to a backing card.
Samples were premixed with AuNP antibody conjugate and applied to test strip. Capillary action
allows the sample and antibody conjugate to wick up the test strip where it will bind accordingly
if sufficient sample is present. The biomarker of interest will bind to both the AuNP conjugate and
to the test line with an antibody specific to biomarker in a sandwich like fashion. This will show
visibly red and the intensity will vary based on the amount of biomarker present. Any AuNP
antibody will bind to the control line which has an antibody specific to the Fc domain and will also
show a red stripe with varying intensity based on concentration.

increases the overall cost and would require testing to be done at testing sites like those used during
the Covid-19 pandemic.
However, even with fluorescent tags and readers, the detection limit of many biomarkers
can fall below the detection limit of fluorescence detection in LFI tests. This study evaluates the
hypothesis that a portable x-ray fluorescence (pXRF) instrument could detect the AuNP
conjugated antibodies bound to the test line at a detection limit lower than visualized tests or
fluorescent tests. pXRF is an analytical instrument that is used for elemental analysis of
archeological artifacts, minerals, plants, and various materials
78

135

. It has also been used more

recently in the biological field to measure animal and peripheral blood specimens

136, 137

. This

convenient technique can be used under ambient conditions to quantify elements from Sodium to
Uranium. We propose pXRF can be used on LFI tests to detect and quantitate if any non-visible
gold is bound to the test and control lines of LFI tests.
The goal of this paper is to determine if pXRF can detect gold nanoparticles bound to test
and control lines on LFI tests at a lower detection limit than existing LFI tests. If this works, pXRF
detected LFI tests will combine the speed and cost of LFI tests with the lower detection limits of
PCR.
Herein, we use pXRF measurements to quantify AuNPs bound to the background, the test
line, and the control line in a pregnancy test. We used purified human chorionic gonadotropin
(hCG) as the positive biomarker in these LFI test strips. We used pXRF to measure elemental
levels of gold and also visual methods to evaluate seLFI strips and compared the results of these
in house seLFI strips to that of commercially available LFI strips. Our findings suggest the pXRF
is a useful tool for LFI development as well as for increasing sensitivity.

B.3

Methods

Lateral flow Immunoassays: The method used to run seLFI tests is illustrated in Figure B.0.2.
The seLFI tests were run in a vertical flow format with 90 µL of blocking buffer (Tris Buffered
Saline with 1% Tween and 0.1% dry milk), 10 µL of pre-conjugated AuNP anti-hCG antibody
from Fitzgerald Industries, and
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A)

B)

C)

D)

E)

F)

G)

H)

I)

Figure B.2 seLFI Wash Procedure
The seLFI test strips were evaluated by A) preparing 100 µL samples that were prepared with
various concentrations of hCG in blocking buffer containing 10 µL of pre-conjugated anti-hCG
antibody bound to AuNP’s. B) The LFI strip is placed into sample. C) The anti-hCG-AuNPconjugate binds the hCG and migrates up the LFI strip. The AuNP-conjugate binds at the control
or test lines. D) While the test is running 100 µL of blocking buffer was prepared. When the
sample had saturated the top control line the seLFI strip is moved to E) as a washing step. This
helped to clear the pink non-specifically bound AuNPs from the background as blocking buffer
washed any nonspecific bound AuNP in the background to the top of the test strip. F) The resulting
sample showed reduced background signal. G) The resulting strip had reduced background signal
but still had a visibly pale pink background. H) The residual gold background signal was further
reduced by performing three five-minute washes in blocking buffer. I) The resulting samples had
significantly improved clearance in comparison to the unwashed samples.

various concentrations of hCG (0 -5.38 μg/mL). The seLFI strip was placed into the solution and
the sample flowed up the seLFI test by capillary action. Once the sample had saturated the top
control line, the strip was moved into a new tube containing 100 µL of blocking buffer and allowed
to run for 1 hr. After the samples had run for 1-hour they were transferred into washing containers.
Each strip was shaken in 5 mL of blocking buffer for 5 min. The buffer was emptied, and the
blocking buffer wash procedure was repeated two more times. After washing the test strip was laid
flat to dry. After the test strips had dried, they were quantified with the pXRF.
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Commercially Available hCG LFI tests: A commercially available hCG pregnancy LFI strip from
ClinicalGuard® (Item # THCG25ZZ) was used as a reference for comparison to our seLFI strip
tests. ClinicalGuard® test strips were placed in a solution of 90 μL blocking buffer (TBS with 1%
tween and 0.1% dry milk) and 10 μL of pre-conjugated AuNP anti-hCG antibody (Fitzgerald 62H25C), and then spiked with varying amounts of hCG. After the initial run, the test strip was placed
in the 100 μL of blocking buffer to wash the test of background AuNPs. Strips were left in the
blocking buffer for 1 hour then laid flat to dry. After the test strips had dried, they were quantified
with the pXRF. The washing procedure was less stringent for the commercial test because it had
an absorbance pad that efficiently pulled the gold nanoparticle-antibody conjugate through the test
strip.

pXRF Imaging: Schematic showing flow of running tests to quantifying gold is shown in Figure
B.3. Quantification of test and control lines was performed by testing the background (a location
on the test that did not correspond to a test or control line), the test line, and the control line.
Quantification was performed using a Bruker Tracer 5i handheld XRF with an 8 mm collimator
and a copper, titanium, and aluminum filter with the respective metal widths: 75 µm, 25 µm, and
200 µm. All measurements were taken using an incident x-ray energy of 42 keV and 67 currents
for 180 seconds ambient conditions. Using Artax software we quantified the amount of AuNPs
using the Lβ1 band for gold at 11.4430 keV representing the electronic transition of L2-M4.
Placement of test strips was standardized with a self-made strip holder. The 3D holder was
employed to hold the LFIs in consistent locations that analyzed only the location of the test or
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control lines or a location that corresponded with the background of the test (Figure B.6). The three
samples were measured three different times in each of the three positions.

Figure B.3 Experimental Schematic for pXRF Quantification of LFIs
LFI samples are run in a buffer with AuNP antibody conjugates. The sample and AuNP
conjugates wick up the strip. Once sample has reached the top of the strip, strips are then laid
flat to dry. Following this the test and control lines are quantified using the pXRF to measure
the amount of gold conjugated to the antibody of interest. The XRF spectrum on the right
shows the the incident emission spectrum. We quantified gold levels using the Lβ1 electron
transition energy to its Gaussian like distribution and low interference with other elemental
transitions.

B.4

Results
The original seLFI half strip, shown in Figure B.4A, shows a purple background signal

throughout the test. We were able to decrease the purple background by doubling the length of
the test where the longer strip acted as an absorbance pad (Figure B.4B). The background is
lighter, and the test and control lines show more distinctive lines and the excess AuNP was
cleared and is observed at the top of the test. Even with the longer seLFI strip, the background
still appeared pink due to non-specific binding of AuNPs. In Figure B.3C we introduced the
chase buffer and washing steps mentioned in . The chase buffer and washes provided a decrease
in pink color from AuNP nonspecifically bound to the paper and the residual gold signal in the
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Figure B.4 seLFI Strip Modifications to Enhance
Sensitivity
All strips show two lines. The bottom line is the test line
and the top line is the control line. A) Original seLFI
strip had high background signal from nonspecifically
bound AuNPs. B) Elongated seLFI strip shows a
reduction in background signal because the longer
paper acted as an absorbance pad. C) Elongated and
washed seLFI strip showed the most significant
reduction in background signal. These samples were
used for pXRF quantitation. D) Amazon LFI for an
example of gold standard clearance from an absorbance
pad and visual sensitivity. All samples were run at 25
μg/mL hCG.
A

B

C

D

background was further reduced by performing three five-minute washes in the blocking buffer.
The resulting test strips had significantly reduced background signal in comparison to the
unwashed sample resulting in increased visual sensitivity. We proceeded with a quantitative
assessment on the amount gold bound to the control and test lines as well as the background in
the washed test strips using pXRF.
We evaluated the best energy transition peak to quantify gold in the XRF spectrum as
shown in Figure B.5. The ideal pXRF peak for elemental analysis quantitation will have a
Gaussian distribution. Other elements like zinc appear in the spectrum and overlap with the more
intense peaks for gold making the gold peak appear lopsided or non-Gaussian. We found that
although the Lβ1 transition for the L2-M4 fluorescence emission is not the most intense peak for
gold, it did have less interference of other elements138. There are other energy level transitions
that could be used but the Lβ1 had the least amount of background for other elements present in
our sample matrix. Therefore, we chose this peak for quantitative analysis of gold bound at the
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Figure B.5 pXRF Spectrum for Gold
The top XRF spectrum shows electronic transition energies
along the x-axis. The intensity of these transitions corresponds
to the elemental abundance of a compound. In top graph we see
the entire spectrum of a test line on the seLFI strip. There are
several peaks that can be analyzed for gold. The Lβ1 XRF peak
for gold at 11.4430 keV. This peak correlates with the electronic
transition from the L2-M4 energy levels. This peak was chosen

as it has no Zn interference as shown in the zoomed-in lower
spectrum.

test and control lines. We compared the intensity of the Lβ1 peak when evaluating differences
between AuNP levels in the background, test line, or control lines.
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The pXRF results for the background, control lines and test lines of the washed seLFI tests are
shown in Figure B.6. We see that samples consistently have reduced background signal after
wash steps. The resulting S/N ratio of 76 was calculated for the test line on the washed strips
shown in Figure B.6. This S/N is more than five standards deviations above the background
signal for gold. We did not introduce quantitative measurements on the seLFI strips before we
introduced the washing steps.

Figure B.6 seLFI Strips & pXRF Quantifications
Three identical seLFI samples, photo to the right,
were run with a 0.484 ng/mL concentration of hCG.
Each sample was analyzed by the XRF in triplicate.
P values were calculated using an ordinary one-way
ANOVA. P<0.0001=**** using n=3 measurements
per sample.

The washed seLFI strips gave proof of concept data showing quantitation of the test and
control lines can be done with pXRF on LFI tests but the seLFI strips have poor reproducibility
in terms of test and control line distance, width, and linearity. We used an 8 mm collimator to
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collimate the excitation energy. This means that we evaluated samples with an 8 mm circular
area. The placement of the lines was not exact from strip to strip, and this variation led to
averaging with more background leading to decreased reproducibility in the results. Due to this
variability in the striping method and strip construction of our seLFI strips we decided to
evaluate the use of pXRF on a commercially available LFI test. The commercial LFI test strips
have more reproducible test and control lines.
The pXRF analysis using the commercially available ClinicalGuard® LFI test strips are
shown in Figure B.7. As the hCG concentration increases the visibility of the test line increases
(Figure B.7A) and the quantity of AuNPs bound at the test line is quantitated by pXRF (Figure
B.7C). When high concentrations of hCG were added (2.7 and 5.38 μg /mL) the intensity of the
control line begins to decrease (Figure B.7A and Figure B.7B). This shows that when the hCG
concentration is very high, most of the gold binds to the test line and less gold is available for
binding at the control line. The pXRF scans show this trend quantitatively in Figure B.7. Our
results show that the pXRF has a limit of detection of approximately 0.025 μg/mL on the
ClinicalGuard® LFI test.

B.5

Discussion
The goal of this work was to evaluate the usefulness of printer paper LFI tests and to

develop methods to improve the limit of detection of AuNPs bound at the test and control lines.
We observed that the short half-strip seLFI tests had high AuNP background compared to longer
seLFI tests or commercial tests with an absorbance pad (Figure B.4). At higher levels of
biomarker, all tests showed positive results but background from AuNPs would prevent
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A)

B)

C)

Figure B.7 Commercially Available LFI Strips & pXRF Quantification
Commercially acquired strips were treated with different amounts of hCG hormone. Each
concentration was run in triplicate. A) Shows an image of the test strips. Image of blank strip was
omitted. B) The quantification of the control line. C) The quantification of the test line. P values were
calculated using an unpaired t-test. n=3 measurements for each concentration. P<0.03=*, P<0.0012=**
P<0.0008=***, P<0.0001=****.

visualization of weak positive test lines in the seLFI half strip because the signal would be lost in
the background. We determined that longer seLFI strips gave improved AuNP clearance that will
improve the ability to visualize positive results.
To properly evaluate the pXRF for quantitative analysis of the LFI tests, we needed to
lower the AuNP signal in the background of the tests. To decrease the AuNP background signal
we elongated the seLFI test strips and introduced a chase buffer and washing steps (Figure B.2,
Figure B.4). The improved clearance of AuNP from the background allowed the evaluation of
pXRF as a quantitative reader of LFI tests.
The introduction of wash steps introduces more opportunities for user error or variability. In the
seLFI strips we did not use a sample or absorbance pad, both of which are known to help in clearing
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the background levels of AuNPs139. Another alternative to minimize background signal from
AuNPs employs bovine serum albumin (BSA) in the running buffer140. BSA (68 kDa) is a protein
that is smaller than antibodies (~250 kDa) and will wick up the test strip faster than the antibodyAuNP conjugate blocking the test strip and mitigating non-specific binding of AuNPs. We chose
not to use BSA because we were investigating low resource options in this simple LFI and used
the minimal buffer components to keep the testing conditions simple. Additionally, elongating the
test strip also increased run time to 1 hour. The combination of a longer run time and introducing
more steps increases the time it takes to run and analyze a test to about 2.5 hours. This would no
longer provide a “rapid” test option meaning results in <30 minutes133, 141.
Since one of our goals was a proof-of-concept study to evaluate pXRF as a detection
method for the seLFI test, we proceeded with the longer washed seLFI tests to evaluate pXRF.
Figure B.5shows the spectrum of the test and control lines. Some intense gold peaks are
observed but several of the gold peaks are close to zinc peaks that could interfere with properly
quantifying the gold. We chose the Lβ1 XRF band for gold at 11.4430 keV which is the
electronic transition of L2-M4 because as it has no zinc interference. We recognize that choosing
a more intense gold peak will allow a lower limit of detection to be obtained but might require
the use of metal free buffers or chelators to eliminate interfering metals.
In this study, only one size of AuNPs were used. Using a larger sized AuNP will provide
increased the pXRF signal and lower the limit of detection. Additionally, there are many other
types of nanoparticles to explore. Strategically choosing metal nanoparticles that have intense
absorbance peaks in the pXRF spectrum is an option to increase sensitivity of this method. Other
metals may also have peaks in the pXRF spectrum that do not have overlap from other metals.
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Additionally, exploring simplified running buffers or metal free buffers could also aid in
improving the pXRF analysis.
We tested the pXRF on commercially available LFI strips with much more accurate
deposition of antibodies with carefully deposited test and control lines (Figure B.7). In a series of
tests evaluated at different biomarker concentrations, the commercial test performed well. The
test and control lines could be evaluated quantitatively using pXRF (Figure B.7B and C).
Interestingly, in the ClinicalGuard test in Figure B.7A we see visually that as hCG
concentrations increase more gold binds to the test line and less gold binds to the control line.
This data supports the idea that there is a finite amount of gold in the test and that quantity is
sufficient to obtain a positive or negative answer with the test.
The results of the ClinicalGuard® LFI test strips from Figure B.7 are helpful to
understand common limits of detection when building a strip. If the goal is to target a positive
test for lower or specified concentration ranges, the concentration of test line antibodies and
conjugate antibodies need to be increased or amplified in order to visually see the test line. The
limit of detection for the ClinicalGuard tests is advertised as 25 mIU/ml which is equivalent to
approximately 2.5 μg/mL using a conversion of 0.1 IU=1mg. Our results suggest that the pXRF
is able to lower that detection limit to 0.025 μg/mL which is a 100-fold increase in detection with
the current pXRF settings.
The results from pXRF quantitation also give insight into the amount of AuNP-antibody
conjugate needed for a test. Supplying the correct quantity of AuNP-conjugate antibody for the
specific levels of antigen required for a positive test is critical. For a pregnancy test, where a
positive or negative answer is required, an excess amount of AuNP-conjugated antibody is
required to see both a test and control line. In other words, if a sample had too much hCG it
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could potentially bind all of the AuNP antibody conjugate to the test line resulting in nothing
binding to the control line. However, for a quantitative LFI test, it is important to understand the
AuNP-conjugated antibody quantity to know how to interpret the result. For example, a known
total concentration of a limited quantity of AuNP-conjugated antibody could allow quantitation
by measuring total AuNP captured and determining the difference in AuNP bound at each line.
Other tests might be designed so that the test and control lines can be completely saturated to
validate a quantitative number. More research here is needed to develop these quantitative
analysis methods.

B.6

Conclusion
The pXRF is a viable quantitative companion tool for evaluating sensitivity in the

development of LFI techniques. The pXRF quantification helped us to increase the detection
limit by a factor of 100 in commercially available strips. The pXRF can quantitatively define
differences in gold nanoparticle concentrations. New method combinations of sensitization and
quantification should be explored to allow for the detection of low-level biomarkers.
Functionalized gold surfaces can provide quick chemistry to bind more visible compounds like
larger nanoparticles with higher extinction coefficients. Investigations on other electronic
transition peaks in the XRF spectrum could provide a peak with higher sensitivity for LFI
evaluation. It is important to keep in mind that some added steps to improve sensitivity in
quantification may compromise the user-friendliness of LFI tests as well as the time to run the
tests. Aside from introducing a reader and wash steps, other methods can be employed to
increase the sensitivity of LFIs. Including some listed in recent reviews.139, 142
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Appendix C. Elemental Mapping of biological samples using portable XRF
Naomi Flindt, Jill Clapperton, Bruce Kaiser, Richard Watt

C.1

Abstract

Iron and other metals mechanisms of transport throughout the body are not fully
understood in part because we don’t have accessible tools that can sensitively investigate metal
localization. I explored the limitations and possibilities of using portable x-ray fluorescence
(pXRF) to investigate metal localization in biological samples including cell lysates and animal
tissues. While the pXRF has potential its current limitations include sensitivity and pixel size.

C.2

Elemental Mapping: A Potential Diagnostic Tool

A hallmark of AD is the accumulation of Fe, Zn, and Cu deposits in the brain. Diabetes,
arthritis, macular degeneration, and other chronic inflammatory diseases that are precursor diseases to AD all show disruptions in metal homeostasis.45, 143 The role that metals play during
chronic inflammation is not well understood. Most research tends to focus solely on iron
however we are finding that iron and other metals are often found localized together. FPN, Ft,
DMT1 and other iron regulatory proteins have shown to transport and store metals other than
iron. Understanding the interplay between iron and other metals is key to understanding
inflammatory related mechanisms. For example Zinc metallothionein (MT) releases Zn+2 with
concomitant oxidation of cysteine residues as an antioxidant mechanism to quench iron induced
ROS in the KEAP1-Nrf2 pathway.144 Copper is found in hephaestin (HEPH) and ceruloplasmin
(Cp), proteins that bind to the iron transporter (FPN). These copper proteins are ferroxidase
enzymes that oxidize iron as it leaves the cell to facilitate Fe+3 loading onto TFN. How hepcidin
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affects these metals and metalloproteins and their respective metabolic pathways is not fully
understood. Other metalloproteins and peptides that are known to have crossover with iron and
other metals include super-oxide dismutase (Cu, Zn), catalase (Mn), and xanthine oxidase (Mo).
Hepcidin is present systemically in the bloodstream and comes primarily from the liver. It
has been shown that hepcidin alters the content of iron in the liver and other organs.4, 9, 28, 92, 145
Other organs such as the spleen, kidneys, heart, and brain also respond to the hepcidin/FPN axis
as cited earlier. In the work of Cavey et al.47 molybdenum and manganese have different trends
in the spleen and liver in response to hepcidin. This data shows that organs respond differently to
hepcidin. Understanding hepcidin’s influence on each organ is key to characterizing which
organs are most susceptible to metal accumulation in response to inflammation. Multi-elemental
analysis is a challenging task especially in biological samples.
Previous models such as the work of Milanino et al.146 have studied the effects of acute
inflammation and arthritis on copper and zinc localization in the kidneys, liver, spleen, and
blood. These studies have been limited to a small subset of metals and organs. Ma et al.147
investigated the distribution of 18 elements across kidney, liver, brain, and heart in 26 different
mammalian species. This study broadened the scope on the number of metals and made
hypotheses to their correlation with metalloprotein and ROS levels but never quantified or
correlated them.
Previous metal quantitation studies were performed via colorimetric or ICP-MS assays
alone.13, 148 While inductively coupled mass spectrometry (ICPMS) and colorimetric methods are
popular, they have limitations due to laborious sample preparation, cost of equipment, and
sample destruction.13, 148 Mass spectrometry can be limited by the ionization efficiency of the
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sample. This limitation often occurs in complex sample matrices, like biological samples, and
can alter ICP-MS results.
There have been several recent advancements in XRF instrumentation particularly, the
Bruker Tracer 5i. The Bruker Tracer 5i is a handheld laboratory grade XRF that can detect
elements from Mg to Ur. The Tracer has a 10-40 keV energy range and a silicon diode detector.
Detector advancements, collimators, and filters allow for more precise measurements and
improved resolution. Additionally, the matrix effects that are a limitation due to ionization
efficiency in ICPMS are not an issue with XRF.149 These improvements in instrumentation make
biological analysis on portable XRF a viable method for developing a quicker and easier method
for multi-elemental analysis in biological tissues. I explored the limitations and possibilities of
using portable XRF to investigate metal localization in biological samples.135, 137, 150 When
appropriate I used ICP-MS as a comparative technique.

C.3

Methods

samples were from a previous rat study.118 Lewis rats were treated with an lipopolysaccharide
(LPS) injection to mimic bacterial infection. Half the rats were treated with Nelfinavir which
significantly lowered hepcidin and iron levels in different organs. Using these known controls,
we reinvestigated the iron levels in the soleus as well as other metal levels using pXRF. Mouse
placenta samples were a gift from the Ganz Lab at UCLA. They were paraffin embedded and
sectioned onto Chemplex Etnom® film and shipped to us on dry ice. Mouse healthy control liver
and kidney samples were a gift from the VanRy Lab at BYU.
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Digested Tissue Quantification:Chicken liver sampling Tyson brand Chicken livers were
prepped in three different ways and analyzed on the XRF. Whole livers were analyzed first.
Livers were then sliced into section with a scalpel and analyzed. Following these measurements
livers were homogenized in RIPA buffer and analyzed. For analysis of homogenate 1 mL
samples were placed over the aperture on top of a Chemplex Etnom® film (Chemplex cat# 095)
secured with a sample cup (Chemplex cat#3115). Samples were analyzed on the XRF in
triplicate.

ICPMS:Homogenates were weighed and suspended in trace metal grade HNO3 at 100 mg/mL.
Samples were sealed and digested at 65°C overnight. Following this samples were centrifuged
and 50 μL of digested sample were diluted to 5 mL in Milli-Q water. Chromium was added as an
internal standard. Samples were filtered using a 0.45 μm PES filter prior to analysis. and
standards were diluted in 3% nitric acid, sonicated, and filtered. Samples were run on the Agilent
and the samples analyzed by ICPMS.

Whole Cell Lysates: HepG2 cells were grown and investigated with XRF and ICPMS. It seems
that matrix effects could be playing a major role in the ICPMS samples. HepG2 cells were grown
to 80% confluency in a T-175 plate. Cells were starved of iron for 24 hours prior to induction
and then treated with 0, 10, and 25 μM iron citrate for 24 hours. After 24 hours, media was
collected and cells were detached from the plates and pelleted in the centrifuge. Cell pellets were
rinsed three times with PBS and lysed in 500 μL of RIPA buffer. For analysis a 100 μL droplet
of media or lysate sample was placed over the aperture on top of a Chemplex Etnom® film.
Samples were analyzed on the XRF in triplicate.
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Whole Tissue Imaging: Mouse livers from healthy control mice were cryo-embedded with OCT
and sectioned in 50 μm sections onto Chemplex Etnom® film slides for XRF metal localization
analysis. Mouse kidneys from healthy control mice were sectioned onto glass slides (Thermo
Scientific) in 50 μm sections. One set of kidneys were stained with a Perl’s Prussian Blue Stain
kit (Polysciences cat#24199-1).

pXRF Imaging: Measurements were taken using the 0.7 mm collimator under helium with
various incident x-ray energies, currents, integration times, and filters. Each image will specify
the instrument settings. All measurement and quantification were made using Artax software.
Imaging samples were mounted to a motorized stage to raster over image.

C.4

Results

First, I investigated the limit of detection for iron using the pXRF in a simple aqueous
matrix. Results are shown in Figure C.1 below. I compared the limit of detection to that of the
ICP optical emission spectrum (OES). For the settings on the pXRF the limit of detection was
lower about 50 times higher than that of the ICP-OES. Considering that the pXRF is significantly
less expensive than the ICP-OES it can still aid in investigating biological samples if we have a
large enough sample size. I investigated whether an increased integration time may aid in
lowering the detection limit as shown in Figure C.2 below. Sixty seconds of integration led to a
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Figure C.1 pXRF Limit of Detection (LOD) Compared to
ICP-OES
LOD Samples were analyzed using an incident x-ray energy of
42 keV and 67 currents for 30 seconds under helium.
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Figure C.2 Integration Time Experiment
Samples were analyzed using an incident energy if 42 eV and
67 currents for various integration times.

higher detection limit to 59 μM detection limit as opposed to 45 μM when integrating for 30
seconds. One issue with iron is that it is very abundant in water and dust. Contamination can
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become an issue. Further studies should be done using iron free water and acid cleaned
containers.
I investigated the detection limits of copper using a simple aqueous matrix. I investigated
the difference in the detection of copper at two different settings as shown below in Figure C.3.
The 5010 represents an incident energy of 50 eV and 10 currents while 4267 represents the
settings used previously of 42 eV and 67 currents. Both use the red filter made from a copper,
titanium, aluminum alloy. The use of the filter helps us to selectively probe a lower range of
electronic transitions. This helps to prevent our spectrum from becoming oversaturated by
electronic transitions that are not in our scope of interest. We see that the LOD for the 4267 was
0.26 μM and 1.073 μM in the 5010 settings. The settings at 4267 are more than four times as
sensitive. We decided to continue probing for both iron and copper with these settings.
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Figure C.3 Copper LOD Investigation
We investigated the use of different incident energies, currents, and filters. One the left we
used an incident energy of 50 eV and 10 currents. On the right results for the typical incident
energy of 42 eV and 67 currents. Both used a 30 second integration time, helium, and the red
filter

Next I was curious to know if these LODs were still in range for biological samples. We
also wanted to introduce more complex sample matrices, we wanted to see if that would hinder
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our measurements. In order to amplify our signal, we decided to begin with an iron overload
induction. In Figure C.4 below we see a difference between iron levels in the HepG2 cells
between the control cells grown without added iron and the iron overloaded cells treated with 25
μM iron. We also experimented with integration time and we see that sample variation decreased
when integrating for 60 seconds. This led to more significant differences between treatments. It
seems that RIPA buffer had a similar iron content to that of water. This implies that iron
quantification via pXRF may not be as susceptible to matrix effects often found in ICPMS.
HepG2 Lysates Iron Overload
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Figure C.4 pXRF Iron Quantification in HepG2 Cell Lysates
We used the incident energy of 42 eV and 67 currents with the red filter and helium. Samples
were induced for 24 hours with various treatments of iron citrate added to media. Lysates were
digested and analyzed in RIPA buffer.
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Figure C.5 Iron Quantification in Fibrotic and Iron Overload HepG2 Cells
Samples were quantified using an incident energy of 42 eV and 67 currents with the red
filter under helium with a 60 second integration time.

Next we were excited to understand whether iron content could also be quantified in the
media and how this content compared with iron quantification results in ICPMS. We induced
with iron overload as well as TGF-β to induce fibrosis. Our hypothesis is that iron is sequestered
in fibrotic cells. The pXRF results in Figure C.5 show that iron increases in both TGF-β induced
cells as well as iron overloaded cells. It is interesting to note that iron also increases in the media
when induced with TGF-β. This could be due to some cells dying off prior to collection. This
data would be more meaningful if it was normalized to protein content, confluency, or total
number of cells digested. On the other hand, the ICPMS results were normalized to protein
content and reveal a different trend. It seems the control sample had the highest amount of iron
while the iron overloaded sample had the lowest amount of iron. This could be due to issues with
matrix effects in ICPMS and the sample preparation process.
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Iron Levels in Digested Tissues

In order to conserve samples, we used purchased Tyson chicken liver for use in our
experimental parameter investigation. Shown in Figure C.6 below digesting or looking at whole
liver intact yielded similar results for our biological replicates. It is interesting to note that the
intensities were much higher in the whole liver than in the homogenate. This is most likely due
to a higher sample concentration for the whole liver, where the homogenate has a dilution effect
from the buffer. This may work for the liver but more investigations need to be done on other
tissue types. Organs that are more heterogeneous may pose more of a sampling issue.
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Figure C.6 Sample Method Comparison for pXRF on Liver
Two sample preparations were compared. Whole liver measurements and homogenized samples
in RIPA buffer. We also compared these XRF results to that of the ICPMS.

Seeing that whole liver gave the same trend in iron as that of homogenate on the XRF. It
seems that sample preparation does not make a big difference assuming thickness of sample does
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Figure C.7 Comparison of Iron in Soleus
Muscle in Lewis Rats
Rats were inflamed via LPS injection and
treated with Nelfinavir. We evaluated levels
of iron in the soleus tissue to see if treatment
groups had altered levels of iron. XRF
measurements were taken with an incident
energy of 42 eV and 67 currents with the red
filter under helium with a 30 second
integration time.
not vary significantly. We decided to continue to investigate trends of whole tissue iron in other
organs such as muscle. We used Lewis rat soleus muscle from a previous animal study. The set
up for this animal study is shown in Figure C.7. Although no significant differences were found
we were excited about seeing a potential trend. It would have been better to have inestigated iron
levels with an increased integration time as this has been shown to decrease sample variation.
Additionally these samples were not normalized in anyway. Normalizing them by thickness may
provide more definitive results. Using sectioned tissue samples may provide a more uniform way
of analyzing tissues.
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Figure C.8 Placenta Elemental Localization
Paraffin embedded mouse placenta were sectioned into 20 μm sections onto Etnom® film.
Elemental localization using pXRF at an incident energy of 25 eV and 90 currents using the
yellow filter and a 0.7 mm collimator. Images were produced using Artax software.

Iron localization in Mouse Tissue

In addition to whole tissue probing, we have been exploring the use of the handheld XRF
to scan over tissue slides to define the localization of metals within an organ. This imaging
technique provides a unique perspective as to where the metals are localizing within the organ
and can provide information on the mechanism of metal localization during inflammation and
disease. To begin our investigation, we used paraffin embedded mouse placenta from the Ganz
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Figure C.9 Mouse Liver Elemental Imaging
Mouse livers were sectioned at 50 μm onto glass slides. The top two rows show elemental analysis
of the plain sample. The bottom two rows show the localization for the Prussian blue stained
sample. Images were taken using an incident every of 25 eV and 90 currents with no filter using
the 0.7 mm collimator and 30 seconds of integration.

lab at UCLA. Figure C.8 shows a picture of the placenta tissue mounted on the film. The spectra
on the right show the localization of iron, potassium and calcium. It seems that potassium has the
best outline for where the tissue is and may be in the paraffin wax. Iron looks slightly more
localized. We employed the use of two other setting but found the 25 eV and 90 currents with the
yellow filter worked the best for seeing iron while mitigating background levels from paraffin.
The general localization of elements is present although resolution is poor. It may also be that the
103

sample was too thin to produce a strong enough signal. Much of the signal is quenched by
ambient conditions and could be strengthened if run under nitrogen or argon as opposed to
helium or air.
In addition to mouse placenta we also investigated livers and kidneys. We started with
the livers on glass. We stained one with Perl’s Prussian Blue stain and the other was not stained.
We wanted to investigate whether we could use a more accessible sample platform such as glass
and secondly whether samples being investigated for other things could be simultaneously
investigated for iron analysis. It seems there were not as many background matrix effects in the
OCT embedding compound as there were in the paraffin as shown in Figure C.9.
Perl’s Prussian blue staining seemed to enhance the signal for iron in the liver. Further
studies need to be done to investigate whether or not this iron is introduced from the stain or is
amplified by the stain. It is also important to note that background iron levels in glass could have
also played a role in the low sensitivity of the liver on glass. Further studies can and should be
done to improve the sensitivity of this measurement.
Following the analysis in livers we investigated the appropriate settings to analyze several
elements simultaneously in the kidney. The kidney samples were mounted onto Etnom® film
which had much better sensitivity for elements like iron. Images are shown in Figure C.10
below. We see that the lower energy was useful for smaller elements such as sulfur, calcium, and
potassium. While, the higher energy was better at producing a signal for larger elements such as
copper and zinc.
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2090 No Filter

3590 yellow filter

Figure C.10 Elemental Distribution in Kidney
Cryo-embedded kidneys were sectioned at 50 μm onto Etnom® film. Two different settings
were used. The left two columns used an incident energy of 25 eV and 90 currents with no
filter. The right two columns show an increased excitation energy of 35 eV and 90 currents
with the use of a yellow filter. A 30 second integration time and 0.7 mm collimator was used.
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C.5
Discussion
Understanding metal localization can be a useful tool in understanding the roles that these
metals play in disease. Limited accessibility to imaging platforms due to cost and availability can
be a factor in advancing imaging techniques. The use of pXRF as a cost effective alternative has
shown potential in evaluating biological samples such as tissues and cell lysates. We see some
exciting preliminary results in Figure C.0.4 and Figure C.0.5 where differences in HepG2 lysate
and media were observed. Evaluating cell lysates in ICP-MS has been a particularly challenging
task due to matrix effects. It seems that those matrix effects are not as prevalent in the pXRF
results as water and RIPA show similar results unlike in ICPMS. A benefit to using pXRF is the
potential for simpler sample preparation techniques. As we see in Figure C.6 and Figure C.7
where whole tissue was analyzed and trends in iron levels were revealed. It is interesting to note
that these did not compare well with ICP-MS results. ICP-MS is considered the gold standard for
elemental analysis however, laborious sample preparation and matrix effects may be playing a
role in nuanced results. Iron is a particularly difficult to probe element due to issues with
contamination. It is possible that pXRF may not be subject to matrix effects as in ICP-MS.
Normalization techniques for pXRF sample need to be explored. In the work of Cavey et al.47
they employ the use of certified biological reference standards.
Metal imaging provides a new dimension to elemental analysis allowing for metal colocalization analyses. It is interesting that sulfur is consistently an element found localized in the
tissue. This helps to understand where the tissue is. In Figure C.9 we see the localization of iron
and calcium increase after staining with Perl’s Prussian Blue. This is most likely due to element
abundant in the stain. A similar metal bound antibody may be used to target the localization of
different proteins in conjunction with localized metals. This can be particularly useful in
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investigated metal transport proteins like zinc transporters (ZIPs) They have been shown to
transport other metals aside from zinc.
Among the limitations in pXRF the resolution needs to be improved if cellular
localization is to be explored. This would also benefit the organ and tissue imaging as well. In
our images we see some localization to where the tissue is present. Increased resolution could be
provided with the use of a smaller collimator and imaging pixel size. This would require
increased imaging time. Another improvement to increase sensitivity would be to use other
environments such as argon or nitrogen to probe samples. Ideally ambient pressure is critical to
preserve sample integrity however vacuum conditions could also help to improve sensitivity.
We have shown that pXRF can be useful in determining the amount of copper in
biological samples with a reasonable limit of detection. It seems that depending on the sample
type and platform excitation energies and filters must be optimized. As we see in Figure C.10
copper was much more prevalent in the higher excitation images. This is particularly interesting
as the elements with full d-block configurations like copper and zinc require higher excitation
energies to emit their tightly held electrons. This is exciting as zinc and copper are notoriously
difficult to probe via ICPMS and OES due to poor ionization efficiency and stability.

C.6

Conclusion

pXRF has the potential to be a useful technique. This was a preliminary investigation and
further work is required to understand its limitations. Elemental imaging is already being used in
the synchrotron and ICP forms which yields much better resolution however it is difficult and
expensive to access these instruments. Implementing a smaller aperture and gases to prevent
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incident x-ray quenching may improve this methods sensitivity and resolution. Creating more
accessible imaging techniques more available will aid in advancing knowledge in the role that
metals play in disease.
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